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COMBINATION THERAPY WITH AEROSOL IL-2 AND NK CELLS
FOR THE TREATMENT OF OSTEOSARCOMA LUNG
METASTASIS

Sergei R. Guma De la Vega, BS
Supervisory Professor: Eugenie S. Kleinerman, MD
The survival of patients with osteosarcoma lung metastases has not improved in
the last 20 years. Novel alternative therapies are needed. The purpose of this
investigation was to evaluate the efficacy of combining natural killer [NK] cell therapy
with aerosol interleukin-2 [IL-2] for the treatment of osteosarcoma lung metastasis. The
expression of NKG2D ligands was analyzed in five different human osteosarcoma cell
lines and 103 patient samples (47 from primary tumors and 56 from lung metastases).
We discovered that osteosarcoma expresses the ligands for the NKG2D. In vitro studies
demonstrated that NK-mediated killing of osteosarcoma cells is dependent on the
NKG2D-NKG2D ligand interaction and that cytotoxicity correlates with the level of
NKG2D ligand expression. Aerosol IL-2 increased NK cell numbers in the lung but not in
other organs. This increase in NK numbers was due to an aerosol IL-2-induced increase
in NK proliferation that occurs almost exclusively in the lung. Aerosol IL-2 also
increased the NK cell infiltration within the lung metastatic nodules. Compared to
control, NK cell treatment alone and aerosol IL-2 treatment alone, aerosol IL-2 + NK cell
therapy had a higher therapeutic efficacy, as judged by a greater decrease in the
number and sizes of tumors nodules, as well as by a greater increase in tumor
apoptosis. Furthermore, aerosol IL-2 + NK cell therapy significantly improved the
vi

survival of mice with osteosarcoma lung metastasis. In addition, there was no evidence
of IL-2-associated systemic toxicities.
In conclusion, combining NK cell therapy with aerosol IL-2 achieved organspecific NK cell migration and proliferation in the lung and reduced pulmonary
metastatic burden, while at the same time avoided the systemic toxicities associated
with IL-2. We believe that a combination therapy consisting of aerosol IL-2 with NK cell
infusions can be a new and effective therapeutic approach for the treatment of patients
with osteosarcoma lung metastasis.
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Chapter 1:
Introduction: background, rationale and research plan
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Osteosarcoma
Osteosarcoma is the most common primary bone cancer in pediatric
patients. It is the second most common primary malignant bone tumor in the
general population, after multiple myeloma. 75% of all osteosarcoma cases occur
between the ages of 15 and 25 years [1]. It is the fifth most common primary
malignant tumor in adolescence. The most common presenting symptom is pain
at the extremities, usually accompanied by a palpable mass upon physical
examination [2].
The treatment of osteosarcoma originally consisted of surgery with or
without radiation therapy. Overall 2-year survival rates were 15 – 20%. In most
cases, microscopic metastases are present in the lung at the time of diagnosis.
For this reason, osteosarcoma that was only treated with surgery and/or radiation
had a metastatic recurrence of 80% [3]. With the advent of neoadjuvant and
postoperative chemotherapy for primary osteosarcoma treatment, 5 year survival
rates have increased to 68% [4]. The current standard of care consists of surgery
and a combination of high-dose methotrexate, cisplatin, adriamycin and
ifosfamide [2]. However, prognosis for patients with pulmonary metastasis is
dismal, with a 5 year survival of 33% [5].
The most frequent site of osteosarcoma metastasis is the lung (81.2%),
followed by the bone (34.2%) [5]. Most deaths are due to respiratory failure
caused by metastatic burden [2]. The current standard treatment for
osteosarcoma lung metastasis consists of surgical resection with preoperative
and postoperative chemotherapy. Chemotherapy consists of cisplatin,
2

doxorubicin, and high-dose methotrexate with leucovorin. The survival for
relapsed patients is very low, with less than 20 % long term post-relapse survival.
Treatment for recurrent lung metastasis is complete surgical removal of all
metastatic foci. The role of chemotherapy for recurrent osteosarcoma is much
less defined, with no accepted standard therapy [6]. It is imperative to discover
and develop new alternative therapies for primary and recurrent osteosarcoma
lung metastasis.

Immunotherapy for osteosarcoma

Our laboratory has had success with the use of immunotherapy for the
treatment of osteosarcoma in pre-clinical and clinical settings. We demonstrated
that liposomal muramyl tripeptide [L-MTP-PE] activates the tumoricidal properties
of blood monocytes [7]. A Phase II trial demonstrated that L-MTP-PE significantly
increased the progression-free interval and the long-term survival of patients with
relapsed pulmonary osteosarcoma metastasis [8]. A Phase III trial demonstrated
that the addition of L-MTP-PE to standard chemotherapy increased the 6-year
survival of pediatric patients with primary osteosarcoma from 70 to 78% [9]. LMTP-PE has been approved for the treatment of high-grade resectable
nonmetastatic osteosarcoma in the European Union. It has been the first new
agent approved for the treatment of osteosarcoma in the last 20 years [10].
We have also demonstrated the effectiveness of using genetically
modified T cells against osteosarcoma lung metastasis in a preclinical model. We
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found that IL-11R is highly expressed in patient specimens of osteosarcoma
lung metastasis. T cells were genetically modified to express a chimeric antigen
receptor against IL-11R . Treatment with IL-11R -CAR-specific T cells
significantly reduced pulmonary osteosarcoma metastasis in an athymic mouse
model. [11]. The success of these immunotherapies supports the investigation of
other immune-based therapies, such as adoptive natural killer [NK] cell therapy.

Natural killer cells

Human NK cells comprise about 10 – 15% of peripheral lymphocytes [12].
They are considered part of the innate immune system due to their ability to
detect and kill virus infected and tumor cells without prior sensitization [13]. They
play an essential role in immunosurveillance. Patients with lower peripheral
natural cytotoxicity have greater cancer predisposition [14]. Patients with NK cell
deficiencies are more susceptible to viral infection, especially from members of
the Herpesviridae family [15]. In addition to their cytotoxicity, activated NK cells
also secrete a variety of cytokines, including INF , TNF , IL-12, GM-CSF and
MIP-1

, which can activate other members of the immune system [16]. They

themselves can be stimulated by IL-12, IL-15, IL-18, IL-21 and IL-2 [17].
The recognition of a target cell by NK cells is a complex interplay between
inhibitory and activating NK receptors and their respective ligands. CD94/NKG2A
heterodimers and the killer-cell immunoglobulin-like receptors (KIRs) are the
major inhibitory receptors in human NK cells. KIRs play a major role in NK cell
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self-tolerance [18]. They recognize specific HLA-B and HLA-C allotypes, while
CD94/NKG2A heterodimers bind to HLA-E [19]. Loss of HLA is a frequent
adaptive mechanism used by cancer cells to escape cytotoxic T cell recognition.
However, this same mechanism renders them more susceptible to NK
cytotoxicity [20]. In humans, the major activating NK receptors are NKG2D, DNAM1, and the natural cytotoxicity receptors (NCRs) [21]. The NCRs, which
consist of NKp46, NKp44 and NKp30, recognize transmembrane-anchored
polypeptides with immune tyrosine-based activating motifs (ITAM). The specific
ligands for the NCRs are currently unknown, but current data suggest that normal
tissues either do not express these ligands or that they express very low levels of
them [22]. D-NAM1 recognizes poliovirus receptor and nectin-2, both members of
the nectin family. D-NAM1 ligands are expressed in a variety of human cancers.
However they are also ubiquitous on normal tissue. This suggests that NK
activation by D-NAM1 is highly dependent on the HLA status [22]. NKG2D is the
best characterized NK activating receptor. It binds and recognizes MIC A/B and
the ULBP family members. NKG2D ligands are generally absent from normal
cells. MIC A/B is only expressed on GI epithelial cells on healthy individuals. This
is believed to be due to epithelial contact with intestinal microbes. NKG2D
ligands are upregulated under conditions of cellular stress, including viral
infection, classical heat shock and malignant transformation [23]. Therefore,
NKG2D ligands tend to be expressed on a variety of human cancers [24-27].
Activation signals generated by NKG2D-ligand binding can bypass signals
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generated by NK inhibitory receptors [23], rendering NK-mediated killing of
cancer cells possible even in the presence of HLA expression.
NKG2D recognition of its ligand activates NK killing through the secretion
of cytotoxic granules into the intercellular space. Major granule proteins include
perforin, which disrupts the cellular membrane, and the granzymes, serine
proteases that trigger the apoptotic pathway. NK cells also express TRAIL and
FasL, both of which can trigger apoptosis by binding to their corresponding
receptors [28]. In addition to NK killing, target recognition also triggers NK
cytokine production [29]. This further contributes to the overall immune response.
For example, activated NK cells secrete INF and MIP-1 , potent macrophage
activators [17].

NK cell cancer immunotherapy

In 2002, Ruggeri et al [30] demonstrated that the survival of AML patients
treated with T cell-depleted allogeneic hematopoietic transplantation was
significantly increased in the presence of KIR ligand incompatibility form donor to
recipient. KIR ligand incompatibility increased 5 year survival from 5% to 60%. It
also prevented the appearance of graft-versus-host disease. Increased 5 year
survival (from 48% to 87%) was subsequently observed in CML and MDS
patients treated with T cell depleted allogeneic transplantation in the presence of
KIR mismatch [31]. This drastic increase in survival and the leading role NK cells
played in the eradication of said malignancies has increased interest in the use of
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NK cells as potential new anti-cancer therapeutics. NK cell associated graft-vstumor effects have also been reported in patients with pediatric solid tumors
treated with haploidentical stem cell transplantation [32, 33].
A number of phase I clinical trials have been performed to evaluate the
safety of allogeneic natural killer cell transplantation as treatment for AML. These
have demonstrated successful engraftment of the donor NK cells, with little to no
side-effects and with evidence of clinical response [34-36]. However, these trials
required the administration of intravenous IL-2 to maintain in vivo NK expansion.
One of the limiting factors of NK cell therapy is the ability to grow them in
sufficient numbers. The highest dose of NK cells that have been infused into
patients was generated through ex vivo expansion [37]. Several different
methods have been developed for ex vivo NK cell expansion. The uses of both
soluble and membrane-bound IL-15, as well as other cytokines, such as IL-2 and
IL-7, have been studied [38]. Denman et al established an ex vivo method to
expand donor NK cells using IL-2 and a genetically modified K562 artificial
antigen presenting cell [aAPC] expressing membrane bound IL-21[39]. This
method promoted a sustained mean 47,967-fold NK expansion after 42 days, as
well as increasing NK cytotoxicity and NKG2D expression. In addition,
membrane bound IL-21 promoted a significant increase in NK telomere length
and greatly reduced senescence. In contrast, other expansion methods, such as
those using membrane bound IL-15, reduced telomere length, inducing NK
senescence by three weeks.
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We believe osteosarcoma can provide an ideal target for NK cell
immunotherapy. In vitro studies have demonstrated high NK cytotoxicity against
pediatric solid tumor cell lines [40]. Among those susceptible to NK killing are
Ewing’s Sarcoma and osteosarcoma [40-42]. Studies have also report elevated
expression of specific NK activating ligands in osteosarcoma [42]. Additionally,
NK activity and NK absolute counts correlated positively with clinical outcome in
osteosarcoma patients treated with interleukin-2 [43]. Recent studies have also
reported the feasibility and safety of using NK cell therapy against solid tumors in
the lung [44]. Thirty minutes after transfusion, the lung serves as a reservoir for
allogeneic NK cells, before they redistribute to the rest of the body [45]. This
makes the lung an ideal organ for NK therapy.

Aerosol Interleukin-2
As mentioned before, most clinical trials using NK adoptive therapy use
concomitant interleukin-2 (IL-2) to maintain NK activation in vivo [34-36]. Even
trials using ex vivo NK expansion require IL-2. The highest doses of NK cells to
be infused into patients were generated through ex vivo NK expansion using IL2, OKT3 and PBMC feeder cells. Patients received an average of 4.7 X 1010 NK
cells and these cells were persistent in the peripheral circulation. However, tumor
regression was not observed, and the persistent NK cells showed significantly
lower levels of NKG2D expression and could not lyse tumor cells in vitro unless
reactivated with IL-2 [37]. This result suggests that even with high NK numbers,
systemic IL-2 is required for NK cytotoxicity in vivo.
8

IL-2 is a cytokine that augments the growth and cytotoxicity of T and NK
cells, as well as driving T cell differentiation and increasing B cells’ antibody
production [46]. It is a FDA-approved therapeutic for metastatic melanoma [47]
and renal cell carcinoma [48]. However, high dose IL-2 therapy is complicated by
serious, sometimes life threatening side effects, including oliguria, hypotension,
elevated bilirubin and creatinine levels, thrombocytopenia, and capillary-leak
syndrome, which can lead to fluid retention, adult respiratory distress syndrome
and myocardial infarction [49].
We propose to use aerosol IL-2 in order to increase the number of injected
NK cells numbers in the lung, while at the same time avoiding the systemic
toxicities associated with IL-2. The safety of aerosol IL-2 has been established by
several clinical trials. Aerosol IL-2 produces only low to mild toxicities [50]. Cough
is the most common side-effect [51]. Patients treated with aerosol IL-2 report a
better quality of life than those treated with systemic IL-2 [52]. Furthermore, an
increased survival has been reported for patients with lung metastasis from renal
cell carcinoma treated with aerosol IL-2 [50, 53, 54]. Aerosol IL-2 recruits
activated lymphocytes to the lung periphery in a dose-dependent manner, as
measured by broncho-alveloar lavage [BAL] [55]. Aerosol IL-2 therapy in dogs
has also shown very minimal toxicity. As in humans, BAL revealed an increase in
activated lymphocytes [56].
Normally, transfused allogeneic NK cells aggregate in the lung for the first
thirty minutes. This is followed by rapid redistribution to the whole body, with a
predilection for the liver, spleen and bone marrow [45]. We believe that giving
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aerosol IL-2 concomitantly with NK cells will cause the NK cells to be retained
and expanded in the lung.
Aim of Study
Our central hypothesis is that aerosol IL-2 will augment the efficiency of
NK cell therapy against osteosarcoma lung metastasis by increasing their
numbers in the lung, enabling greater contact and interaction with their target
cells. We first determined osteosarcoma’s expression of NKG2D ligands as well
as its susceptibility to NK cytotoxicity. Using Nu/Nu mice we also determined if
aerosol IL-2 increases the number of injected NK cells in the lung. We proceeded
to determine if aerosol IL-2 increases the efficiency of NK cell therapy in mice
with osteosarcoma lung metastasis.
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RESULTS

Chapter 2
NK cells kill osteosarcoma cells in a NKG2D dependent manner
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RATIONALE
The recognition of target cells by NK cells is a complex interplay between
inhibitory and activating NK receptors and their respective ligands. The killer-cell
immunoglobulin-like receptors [KIRs] are the major inhibitory receptors on human
NK cells. They recognize specific HLA-B and HLA-C allotypes [57]. NKG2D is a
major NK activating receptor, specifically associated with tumor surveillance [58].
NKG2D recognizes MIC A/B [59] and the ULBP proteins [60], which are
overexpressed on several cancers [25, 27, 61]. NK-based immunotherapy is
dependent on tumor NKG2D ligand status [58, 62, 63]. In order to determine if
NK cell therapy could be an effective tool against osteosarcoma, we determined
the NKG2D ligand expression on five different osteosarcoma cell lines. HLAA,B,C expression was also evaluated. NK cytotoxicity against these cell lines
was determined and correlated with NKG2D ligand expression. In addition, to
further examine the dependence of NK cytotoxicity on NKG2D ligand expression,
the NKG2D –NKG2D ligand interaction was blocked, with monoclonal antibodies.
RESULTS
Human osteosarcoma cell lines express NKG2D ligands
NKG2D ligands are highly expressed among LM7, CCHOSD, U2OS and
TE-85 osteosarcoma cells (Figure 1). With the exception of KRIB, all cell lines
expressed a high percentage (from 85 to 99%) of HLA-A, B, C and ULBP2. In
addition, MIC A/B was expressed on LM7, U2OS and TE-85, while ULBP1 was
expressed in CCH-OS-D. LM7[64], U2OS [65], CCH-OS-D [66] and TE-85 [65]
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are non-transformed cell lines derived from patient samples, while KRIB was
derived from HOS transfected with v-K-ras [65]. This may explain the difference
between KRIB cells and the 4 other cell lines.

Figure 1: NKG2D Ligand Expression. Human osteosarcoma cell lines were analyzed

for the expression of NKG2D ligands and HLA-ABC using flow cytometry. LM7,
U2OS, TE-85 and CCHOSD cells expressed high levels of NKG2D ligands. Figure
and figure legend were originally published in Pediatric Blood and Cancer 2013.
This material is reproduced with permission of John Wiley & Sons, Inc..

Human NK cells are cytotoxic against human osteosarcoma cells
We determined NK cytotoxicity against LM7, CCH-OS-D, KRIB, TE-85
and U2OS. Since NK-mediated cytotoxicity is species specific, K7M3 mouse
osteosarcoma cells were used as the negative control. NK cells were cytotoxic to
13

all five human cell lines. KRIB cells were the least sensitive to NK-mediated
killing (Figure 2). At 1:1 effector: target [E:T] ratio NK cell-mediated cytotoxicity
against LM7, CCH-OS-D, U2OS and TE-85 cells was 45% compared to 10%
cytotoxicity against KRIB cells. The low level of NKG2D ligands on KRIB cells
correlates with the lower cytotoxicity value.

Figure 2: NK-cell mediated cytotoxicity. NK-cell mediated cytotoxicity against KRIB,
3
LM7, TE-85, U20S and CCH-OS-D osteosarcoma cells was quantified using [ H]-thymidine
cytotoxicity assay. K7M3 mouse osteosarcoma cells served as the negative control. Figure
and figure legend were originally published in Pediatric Blood and Cancer 2013. This
material is reproduced with permission of John Wiley & Sons, Inc..
NK cytotoxicity against osteosarcoma is dependent on NKG2D-NKG2D
ligand interaction
NK cytotoxicity is dependent on the interaction between the NKG2D
receptor on NK cells and its corresponding ligand on the tumor cell. Blocking the
NKG2D receptor significantly reduced NK cytotoxicity against LM7 cells (Figure
14

3A). At 1:5 E:T ratio, 10 µg/ml of anti-NKG2D antibody decreased NK-mediated
cytotoxicity from 70% ± 15 to 22.6% ± 10.8 (P= 0.02). At 1:10 E:T ratio
cytotoxicity decreased from 73% + 6.2 to 12 % + 12.7 (P= 0.02). Similarly
blocking the ligand also decreased NK-mediated killing (Figure 3B). ULBP2 was
selected since this ligand is expressed on all the non-transformed cell lines.
Blocking ULPB2 in LM7 significantly reduced NK mediated killing. At 1:5 E:T
ratio, 10 µg/ml of anti-ULBP2 antibody decreased cytotoxicity from 70% ± 15 to
29.8% ± 10 (P = 0.004). At a 1:10 E:T ratio, cytotoxicity decreased from 73% +
6.2 to 39% + 9.4 (P= 0.01).

A

LM7
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B

LM7

Figure 3: Blocking NKG2D- NKG2D ligand interaction hinders NK cytotoxicity against
osteosarcoma A. NK cells were incubated with anti-hNKG2D prior to the addition to LM7
cells. B. LM7 cells were incubated with anti-hULBP2 prior to addition of NK cell. P<0.05 was
considered significant.
SUMMARY
These data support the concept of using NK immunotherapy against
osteosarcoma. I have demonstrated that human osteosarcoma cell lines express
NKG2D ligands. Accordingly, human NK cells are cytotoxic against these cell
lines. The exception was the KRIB cell line, which had very low levels of NKG2D
ligand expression. The fact that the KRIB cell line was derived from HOS with a
v-K-ras transfection, while the others are non-transformed cell lines derived from
patient samples, may explain KRIB’s low NKG2D ligand expression and,
16

consequently, lower NK sensitivity. I further demonstrated that by blocking the
NKG2D-NKG2D ligand interaction, NK cytotoxicity was hindered. These results
support our hypothesis that NK cytotoxicity against osteosarcoma correlates and
is dependent on NKG2D ligand expression. In potential future clinical trials, the
effectiveness of NK cell therapy against osteosarcoma may be predicted by the
levels of NKG2D ligand expression.
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RESULTS

Chapter 3
The expression of NKG2D ligands in osteosarcoma patient samples.
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RATIONALE
After demonstrating that human osteosarcoma cell lines have an
increased NKG2D ligand expression as well as a high sensitivity to NK killing, we
further investigated the plausibility of NK cell therapy by determining the
expression of NKG2D ligands in patient osteosarcoma samples. Previous
investigations [58, 62, 63] have demonstrated that the status of NKG2D ligand
expression is important for immune surveillance and for effective cytokine
therapies. We have confirmed that NK cytotoxicity against osteosarcoma
correlates with and is dependent on NKG2D-NKG2D ligand interaction.
Therefore, we can predict the effectiveness of NK cell based immunotherapy by
determining the level of osteosarcoma NKG2D ligand expression.
Paraffin-embedded microarray slides of patient osteosarcoma tissues from
the University of Michigan were kindly provided by Dr. Dennis Hughes, MD/PhD
(Division of Pediatrics, The University of Texas MD Anderson Cancer Center).
The tissue microarray slides contained 47 primary osteosarcoma and 56
osteosarcoma lung metastasis samples. We determined NKG2D ligand
expression through immunohistochemistry using a recombinant human
NKG2D/Fc Chimera.
RESULT
NKG2D ligands were expressed in 27(57%) of the 47 primary tumor
specimens. Staining was weak in 18 specimens (38%), moderate in 6 specimens
(12.8%) and strong in 3 specimens (6.4%) (Figure 4A). NKG2D ligands were
expressed in 44 (77%) of the 56 lung metastasis specimens. Staining was weak
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in 22 specimens (39%), moderate in 18 specimens (32%) and strong in 4
specimens (7.5%) (Figure 4B). (Originally published in Pediatric Blood and
Cancer 2013. This material is reproduced with permission of John Wiley & Sons,
Inc.)

Figure 4: Expression of NKG2D ligands on human osteosarcoma tumors.
Human osteosarcoma patient samples from primary tumor (A) and lung
metastasis (B) were analyzed for the expression of NKG2D ligands by
immunohistochemistry using a rhNKG2D/Fc. Positive NKG2D ligand staining
was classified as negative, weak, moderate or strong. Figure and figure
legend were originally published as supplemental material in Pediatric Blood
and Cancer 2013). This material is reproduced with permission of John Wiley
& Sons, Inc..
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SUMMARY
The data also demonstrate that a high percentage of osteosarcoma
express NKG2D ligands. It also demonstrates that osteosarcoma pulmonary
metastasis has a higher NKG2D ligand expression than primary tumors. This
results validate that osteosarcoma lung metastasis could be an ideal target for
NK cell therapy.
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RESULTS

Chapter 4
Aerosol IL-2 increases the number and proliferation of NK cells in the lung
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RATIONALE
In the previous chapters, we have shown that osteosarcoma cells are
sensitive to NK cell killing and that both osteosarcoma cell lines and patient
tissue samples expresses the ligands required for this sensitivity. However, for
NK cell therapy to be effective, a sufficient number of NK cells must come into
contact with their target cells. Since we are specifically interested in pulmonary
osteosarcoma metastasis, we proposed using aerosol IL-2 to increase the
number of injected NK cells present in the lung.
IL-2 is a cytokine that stimulates the growth, cytotoxicity and survival of
NK cells [67]. For this reason, it has been given as an in vivo activator in clinical
studies involving NK cell therapy [68, 69]. Yet, high dose IL-2 induces a myriad of
life-threatening side effects, including oliguria, hypotension, and elevated bilirubin
and creatinine levels [68]. Furthermore, its effects are not organ specific. We
proposed using aerosol IL-2 to stimulate the injected NK cells in the lung
specifically, the most frequent site for osteosarcoma metastasis [70].
Nu/Nu mice were injected with human NK cells and treated with either
aerosol IL-2 or aerosol PBS. The effect of aerosol IL-2 on NK cell numbers in the
lung, liver, spleen, heart and kidney was determined. To further corroborate
these findings, we determined the percentages of proliferating NK cells in the
lungs, spleen, liver and bone marrow.
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RESULTS
Aerosol IL-2 increased NK cells in the lungs
Aerosol IL-2 increased the number of NK cells in the lung 3 days after
human NK cell injection (P = 0.02; Figure 5). There was a slight increase 1 day
after injection when compared to control yet not in a statistically significant
manner (P = 0.26). The number of NK cells in the lung for aerosol PBS treated
mice did not change between 1 day, 3 days and 1 week after NK cell injection.
After one week, the number of NK cells in the lung of aerosol IL-2 treated mice
decreased to levels similar to aerosol PBS-treated mice, suggesting aerosol IL2’s effect on the injected NK cells’ pulmonary presence is time-dependent.
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Figure 5. Aerosol IL-2 increases human NK cells in the lungs. Nude mice were
7
injected with 5x10 CM-DiI-labeled human NK cells per mouse. Aerosol PBS or IL-2 was
given 1 day prior to and on the day of NK cell infusion and then continued every other day
for 1 week. Fluorescent microscopy was used to detect the presence of CM-Dil+ cells
(red) in lungs at 1, 3 and 7 days after NK cell infusion. Cellular nuclei were identified with
Hoechst33258 (blue). Mean positive fluorescence was quantified using the Simple PCI
software in 5 random fields per section. Representative pictures of NK cell presence in the
lung at the different time points are shown. Figure and figure legend were originally
published in Pediatric Blood and Cancer 2013. This material is reproduced with
permission of John Wiley & Sons, Inc..
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Aerosol IL-2 did not increase NK cells in the spleen, liver, heart or kidney
High numbers of injected NK cells were observed in the spleen and liver
(Figure 6 A,B), suggesting that a large portion of infused NK cells localize into
these two organs. However, there was no aerosol IL-2-associated increase. It is
worthwhile to note that there is a non-statistically significant decreasing trend in
the number of NK cells present in these organs when aerosol IL-2 was given.
This is consistent with the increased presence of NK cells seen in the lung. There
was a very minimal presence of injected NK cells in the heart and kidney (Figure
6 C,D) with no increase associated with aerosol IL-2 treatment.
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Figure 6. Aerosol IL-2 does not increase human NK cells in the spleen, liver, heart or
kidney. Mean positive fluorescence was quantified for the presence of CM-DiI+ NK cells in
A spleen, B liver, C heart and D kidney. E. Representative sections from organs 3 days
after NK cell infusion. Figure and figure legend were originally published in Pediatric Blood
and Cancer 2013. This material is reproduced with permission of John Wiley & Sons, Inc..
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Aerosol IL-2 increased the proliferation of NK cells in the lung
We proceeded to determine if the increase in lung NK cells caused by
aerosol IL-2 was due to an increase in NK cell proliferation. For example, the
increase of mouse NK cells observed in the lung after intranasal respiratory viral
infection is not due to an increase of NK cell proliferation in the lung. Instead it is
caused by an increase in proliferation of the NK cells in the bone marrow [71]. To
determine if that is the case for aerosol IL-2 therapy, we injected Nu/Nu mice with
human NK cells and treated them with either aerosol PBS or aerosol IL-2. We
injected these mice with BrdU 3 hours prior to euthanasia and harvested cells
from their lungs, spleen, liver and bone marrow. Cells that stained positive for
human NKp46 and BrdU were identified as proliferating NK cells; cells that were
NKp46+/BdU- were identified as non-proliferating NK cells.
Aerosol IL-2 increased human NK proliferation in the lung. This was seen
by a marked increase in the percentage of proliferating NK cells seen 24 and 72
hours after NK injection (Figure 7). 24 hours after injection, 20% ± 4 of the
human NK cells in the lung of mice treated with aerosol IL-2 were proliferating,
compared to 8% ± 0.15 of those in the lung of aerosol PBS treated mice (P =
0.03). The difference between treatments increased over time. 72 hours after
injection, 76% ± 9.5 of the human NK cells in the lung of mice treated with
aerosol IL-2 were proliferating, compared to 9.2% ± 6.2 of those in the lung of
mice treated with aerosol PBS (P = 0.007).
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Percentage of Proliferating NK Cells (Lung)

Figure 7: Aerosol IL-2 increases the percentage of proliferating NK cells in the lung.
7
Nude mice were injected with 5x10 human NK cells per mouse. Aerosol PBS or IL-2 was
given 1 day prior to and on the day of NK cell infusion and then continued every other day.
BrdU reagent was injected intraperitoneally 3 hours prior to euthanasia. Lungs were
harvested and minced. Single-cell suspensions were prepared by passage through cell
strainers. Flow cytometry was used to identify NK cells with anti-human NKp46 staining and
proliferating cells with anti-BrdU staining. P< 0.5 was considered significant.
Aerosol IL-2 increased the proliferation of NK cells in the bone marrow
A large percentage of human NK cells were proliferating in the bone
marrow, in both aerosol IL-2 and aerosol PBS treated mice (Figure 8). However,
there was an increase in the percentage of proliferating NK cells found in the
bone marrow of mice treated with aerosol IL-2. 24 hours after injection, 93.6 % ±
4.8 of the human NK cells in the bone marrow of mice treated with aerosol IL-2
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were proliferating, compared to 65.5% ± 0.15 of those in the bone marrow of
aerosol PBS treated mice (P = 0.03). 72 hours after injection, the percentage of
proliferating NK cells in the bone marrow decreased. 58.5 % + 1.5 of the human
NK cells in the bone marrow of mice treated with aerosol IL-2 were proliferating,
compared to 23.8% ± 8.9 of those in the bone marrow of mice treated with
aerosol PBS. At 72 hours after injection, the difference between the percentage
of proliferating NK cells between the two treatment groups was not statistically
significant (P = 0.058).
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Figure 8: Aerosol IL-2 increases the percentage of proliferating NK cells in the bone
7
marrow. Nude mice were injected with 5x10 human NK cells per mouse. Aerosol PBS or IL2 was given 1 day prior to and on the day of NK cell infusion and then continued every other
day. BrdU reagent was injected intraperitoneally 3 hours prior to euthanasia. Bone marrow
cells were obtained by flushing femurs and iliac crest with PBS. Flow cytometry was used to
identify NK cells with anti-human NKp46 staining and proliferating cells with anti-BrdU
staining. P < 0.05 was considered significant.

Aerosol IL-2 did not increase the proliferation of NK cells in the spleen or
liver
In both the aerosol IL-2 and aerosol PBS treated-mice, a very low
percentage of NK cells were proliferating in the spleen and liver 24 hours after
NK cell injection (Figure 9). In the spleen, 2.55 % ± 2.55 of the human NK cells of
mice treated with aerosol IL-2 were proliferating, compared to 2.3% ± 2.23 of
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human NK cells in mice treated with aerosol PBS (P = 0.9). In the liver, 5.1 % ±
1.1 of the human NK cells of mice treated with aerosol IL-2 were proliferating,
compared to 4.2% ± 1.6 of human NK cells in mice treated with aerosol PBS (P =
0.72). The difference between the percentages of proliferating NK cells between
the two treatment groups was not statistically significant. At 72 hours, the
percentages of proliferating NK cells increased in the two organs, yet the
differences between the two groups remained statistically insignificant. In the
spleen, 44.1 % ± 8.4 of the human NK cells of mice treated with aerosol IL-2
were proliferating, compared to 23.3% ± 9.1 of human NK cells in mice treated
with aerosol PBS (P = 0.1). In the liver, 11.7 % ± 3.8 of the human NK cells of
mice treated with aerosol IL-2 were proliferating, compared to 16.3% ± 10.7 of of
the human NK cells of mice treated with aerosol PBS (P = 0.74).
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Figure 9: Aerosol IL-2 does not increase the percentage of proliferating NK cells in
7
the spleen or spleen. Nude mice were injected with 5x10 human NK cells per mouse.
Aerosol PBS or IL-2 was given 1 day prior to and on the day of NK cell infusion and then
continued every other day. BrdU reagent was injected intraperitoneally 3 hours prior to
euthanasia. Spleens and livers were harvested and minced. Single-cell suspensions
were prepared by passage through cell strainers. Flow cytometry was used to identify
NK cells with anti-human NKp46 staining and proliferating cells with anti-BrdU staining. P
< 0.05 was considered significant.
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SUMMARY
We have demonstrated that aerosol IL-2 treatment increases the number
of injected NK cells in the lung. In contrast, it does not increase the number of NK
cells in the spleen, liver, heart or kidney. This result suggests that the effect of
aerosol IL-2 on NK cells is organ specific. We further demonstrated that a higher
percentage of NK cells in the lung are proliferating when aerosol IL-2 is given.
This suggests that aerosol IL-2 is directly stimulating the proliferation of NK cells
in the lung. This effect is seen 24 hours after NK cell injection, and continues to
increase at least up to 72 hours after NK cell injection.
Aerosol IL-2 did not increase the proliferation of NK cells in the liver or
spleen. Aerosol IL-2 slightly increased the proliferation of human NK cells in the
bone marrow.
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RESULTS

Chapter 5
Aerosol IL-2 increased the efficacy of NK cells against metastatic
osteosarcoma in vivo
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RATIONALE
Our results have indicated that human NK cells are cytotoxic against
human osteosarcoma cells in vitro. Our results have also indicated that aerosol
IL-2 increases the number of injected NK cells in the lung. We hypothesized that
in the presence of pulmonary osteosarcoma metastasis, aerosol IL-2 would
increase the number of NK cells that come in contact with their target tumor cells,
enhancing killing. In this chapter, I describe how we tested this hypothesis.

Day 0
LM7 I.V.
Injection

Week 5

Week 6

Micro
Metastasis

Week 11
5 Weeks

Treatment
d

End of
Treatment

Figure 10. Schematic diagram of in vivo model experimental design. Nude mice
6
were injected i.v. with 3 x 10 LM7 cells. Presence of micrometastasis was confirmed by
H&E at week 5. Therapy was initiated on week 6. Mice were treated with aerosol PBS,
aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK cells two times per week for
5 weeks
We used our established osteosarcoma pulmonary metastasis model [64].
3 million LM7 cells/mouse were injected intravenously through the tail vein of
nu/nu mice. The presence of micrometastasis was confirmed through H&E at 5
weeks in a group of 3 mice. Treatment was then initiated with aerosol PBS,
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aerosol IL-2, aerosol PBS + human NK cells or aerosol IL-2 + human NK cells 6
weeks after LM7 injection. Aerosol therapy was continued every other day for 5
weeks. NK cell injections (5 x 107 cells/mouse) were given 2 times a week
starting 1 day after the first aerosol treatment. Following the treatment, the mice
were sacrificed and the lungs resected for further analysis (Figure 10).
RESULTS
Aerosol IL-2 + NK cell therapy decreases the number of pulmonary
metastatic nodules
Aerosol IL-2 + NK cell therapy significantly decreased the number of
pulmonary metastatic nodules, when compared to control (aerosol PBS) (P =
0.01), aerosol IL-2 alone (P = 0.03) and aerosol PBS + NK cells (P = 0.01)
(Figure11). Four mice treated with aerosol IL-2 + NK had no visible metastasis
present in the lung. In comparison, only one of the mice treated with aerosol PBS
+ NK cells had no visible pulmonary metastasis (Figure 12). The mean number of
pulmonary metastatic nodules present in mice treated with both aerosol IL-2 and
NK cells was 2.8 ± 1.6, compared to 13 ± 3 nodules for aerosol PBS + NK cell
treated mice, 18.4 ± 5.4 nodules for aerosol IL-2 treated mice and 22.6 ± 6
nodules present in aerosol PBS treated mice. Both aerosol IL-2 alone and
aerosol PBS + NK cell treatments decreased the mean number of metastatic
lung nodules, but the decrease was not statistically significant when compared to
aerosol PBS treatment (P = 0.6 and P = 0.1, respectively).
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Figure 11: Aerosol IL-2 + NK cell therapy decreases the number of
6
pulmonary metastatic nodules. Nude mice were injected i.v. with 3 X 10
LM7 cells. Therapy was initiated 6 weeks later. Mice were treated with
aerosol PBS, aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK
cells for five weeks. Mice were sacrificed, their lungs harvested and the
mean number of metastatic nodules was determined. P < 0.05 was
considered significant. Figure and figure legend were originally published
in Pediatric Blood and Cancer 2013. This material is reproduced with
permission of John Wiley & Sons, Inc..
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Figure 12: Representative picture of lungs of mice treated with aerosol PBS,
aerosol IL-2, aerosol PBS + NK cells and aerosol IL-2 + NK cells for five weeks.
6
Nude mice were injected i.v. with 3X10 LM7 cells. Therapy was initiated 6 weeks
later. Mice were sacrificed and their lungs harvested. Figure and figure legend were
originally published in Pediatric Blood and Cancer 2013. This material is reproduced
with permission of John Wiley & Sons, Inc..

Aerosol IL-2 + NK cell therapy decreases the size of pulmonary metastatic
nodules
Aerosol IL-2 + NK cell therapy significantly decreased the size of the
individual lung tumor nodules (Figure 13). The mean diameter of lung nodules in
mice treated with aerosol IL-2 + NK cells was 1.12 mm ± 0.36, compared to 2.07
mm ± 0.46 for those treated with aerosol PBS (P = 0.005) and 1.9 mm ± 0.42 for
those treated with aerosol IL-2 (P = 0.004). Aerosol IL-2 therapy alone did not
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reduce the mean tumor diameter when compared to aerosol PBS (P = 0.8).
Aerosol PBS + NK cell therapy did seem to decrease tumor size, from a mean
tumor diameter of 2.07 mm ± 0.46 for those treated with aerosol PBS to 1.37 mm
± 0.43. Yet, this decreases was not statistically significant (P = 0.07). The mean
tumor diameter was not statistically significant between aerosol IL-2 + NK cell
and aerosol PBS + NK treated mice (P = 0.4).
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Figure 13: Aerosol IL-2 + NK cell therapy reduces pulmonary metastatic nodule
6
size. Nude mice were injected i.v. with 3X10 LM7 cells. Mice were treated with aerosol
PBS, aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK cells for five weeks. Mice
were sacrificed, their lungs harvested and the diameter of each individual tumor nodule
was measured. P < 0.05 was considered significant. Figure and figure legend were
originally published in Pediatric Blood and Cancer 2013. This material is reproduced with
permission of John Wiley & Sons, Inc..
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Aerosol IL-2 + NK Cell therapy decreases the total surface area of the lung
that was infiltrated with osteosarcoma metastasis
The surface area of each tumor nodule was calculated. The total surface
area of each lung that was infiltrated with metastasis was calculated by the sum
of the surface areas of each of its individual tumor nodules. From these values,
the mean total metastatic area was calculated for each treatment group. Aerosol
IL-2 + NK cell therapy significantly reduced the total area of the lungs covered in
metastases compared to that of mice treated with aerosol PBS (P =0.004),
aerosol IL-2 (P = 0.04) or aerosol PBS + NK cells (P= 0.05) (Figure 14).
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Figure 14: Aerosol IL-2 + NK cell therapy decreases the total area of lungs infiltrated
6
with osteosarcoma metastasis. Nude mice were injected i.v. with 3 X10 LM7 cells. Mice
were treated with aerosol PBS, aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK
cells for five weeks. Mice were sacrificed, their lungs harvested and the total metastatic area
was calculated. P < 0.05 was considered significant. Figure and figure legend were originally
published in Pediatric Blood and Cancer 2013. This material is reproduced with permission
of John Wiley & Sons, Inc..
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Aerosol IL-2 + NK Cell therapy increased tumor apoptosis
NK cell killing is mediated by the secretion of cytotoxic granules that
trigger the apoptotic pathway [28]. We have demonstrated that aerosol IL-2 + NK
cell therapy significantly reduced metastatic tumor burden. TUNEL staining was
used to evaluate if this were due to increased apoptosis in the tumor nodules
(Figure 15). Apoptosis was significantly higher in lung metastases from the mice
treated with aerosol IL-2 + NK cells when compared to mice treated with aerosol
PBS (P =0.009), aerosol IL-2 (P= 0.02) or aerosol PBS + NK cells (P= 0.05).
Aerosol IL-2 and PBS + NK cells also increased tumor apoptosis when compared
to aerosol PBS treatment. However, though the mean of aerosol IL-2-induced
apoptosis was lower than that induced by aerosol PBS + NK cell therapy, its
increase was statistically significant when compared to aerosol PBS (P = 0.003),
while the increase induced by aerosol PBS + NK cells was not statistically
significant (P = 0.17).
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Figure 15. Aerosol IL-2 + NK cell therapy increased tumor apoptosis. Mean
positive TUNEL was quantified using the Simple PCI software in 5 random fields
per section. P < 0.05 was considered significant. Figure and figure legend were
originally published in Pediatric Blood and Cancer 2013. This material is
reproduced with permission of John Wiley & Sons, Inc..
Tumor apoptosis inversely correlates with the amount and size of
pulmonary metastatic nodules.
To further corroborate that the increase in apoptosis is associated with the
decrease in pulmonary metastatic burden, TUNEL values for each lung were
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correlated to the corresponding number of metastatic nodules, mean diameter of
nodules, and total metastatic area using a Spearman Rank correlation (Figure
16). The level of apoptosis inversely correlated with tumor burden, as quantified
by the number of metastases (R = -0.788, P = 0.008), tumor diameter (R = -0.89,
P = 0.008) and metastatic area (R = -0.78, P = 0.0009). This inverse correlation
was validated by a linear regression analysis.
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Figure 16. Tumor apoptosis inversely
correlates with pulmonary metastatic
burden TUNEL Simple PCI quantified
values for each lung were correlated to
the corresponding number of metastatic
nodules, mean diameter of nodules, and
total metastatic area. P < 0.05 was
considered significant. Figure and figure
legend were originally published in
Pediatric Blood and Cancer 2013. This
material is reproduced with permission of
John Wiley & Sons, Inc..
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SUMMARY
Combination therapy with aerosol IL-2 and NK cells significantly reduced
pulmonary osteosarcoma metastasis, as measured by the number of tumors, the
size of the metastatic nodules and by the metastatic infiltration of the lung. This
was accompanied by a significant increase in tumor apoptosis. Tumor apoptosis
inversely correlated with tumor number, tumor size, and metastatic infiltration.
These results suggest that increased apoptosis is the mechanism behind the
observed reduction in metastasis. This was expected, as NK cells kill by
releasing cytotoxic granules that trigger the apoptotic pathway [28].
Giving aerosol IL-2 increases the efficacy of NK cell therapy against
osteosarcoma lung metastasis. Our hypothesis was proven correct by the
significant greater reduction in metastasis and increased tumor killing when
aerosol IL-2 was given with NK cells versus to giving aerosol PBS with NK cells.
Monotherapy with aerosol IL-2 slightly reduced tumor numbers and increased
tumor killing, but to a much lesser degree.
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RESULTS

Chapter 6
Aerosol IL-2 increased the NK cell infiltration of osteosarcoma metastasis
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RATIONALE
We have shown that aerosol IL-2 increases the efficiency of NK cell
therapy, as demonstrated by a reduction in osteosarcoma lung metastasis. This
reduction is correlated with increased tumor apoptosis. Since aerosol IL-2
increases the presence of injected NK cells inside normal mouse lungs and NK
cells kill primarily by activating tumor cell apoptosis [28], we hypothesized that
aerosol IL-2 increased the number of NK cells inside the tumor nodules, thereby
facilitating the physical interaction between the NK cells and their targets.
In this chapter we evaluated the infiltration of lung tumor nodules by
human NK cells through the use of immunofluorescence staining. We also
evaluated the presence of mouse NK cells in the same tumor nodules.
RESULTS
Aerosol IL-2 increased human NK cells in the metastatic osteosarcoma
nodules in the lung
Fluorescent microscopy demonstrated increased human NKG2D staining
in the lung metastasis from mice treated with aerosol IL-2 + human NK cells
versus that from the mice treated with aerosol PBS + human NK cells (P = 0.038;
Figure 17). Thus, aerosol IL-2 increases the contact between injected NK cells
and their target tumor
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cells.

.
Figure 17. Aerosol IL-2 increased human NK cells in lung metastasis.
Fluorescent microscopy was used to determine the NK cell infiltration in the lung
using anti-human NKG2D (red). Cellular nuclei were identified with Hoechst33258
(blue). Mean positive fluorescence was quantified using the Simple PCI software in
5 random fields per section. P < 0.05 was considered significant. Figure and figure
legend were originally published in Pediatric Blood and Cancer 2013. This material
is reproduced with permission of John Wiley & Sons, Inc..
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Aerosol IL-2 increased mouse NK cells in the metastatic osteosarcoma
nodules in the lung
Fluorescent microscopy demonstrated increased mouse NKp46 staining in
the lung metastasis from mice treated with aerosol IL-2 versus that from mice
treated with aerosol PBS (P = 0.05, Figure 18). This demonstrates that aerosol
IL-2 therapy also increases the number of the mice’s own NK cells inside the
tumor. However the presence of mouse NK cells in the lung metastasis was
much lower than the presence of human NK cells. Whether this contributes to
aerosol IL-2’s overall therapeutic effect is unknown. The number of mouse NK
cells was also increased inside metastasis which were given aerosol IL-2 +
human NK cells when compared to aerosol PBS treated mice (P = 0.013).
However, there wasn’t any statistically significant difference in the number of
mouse NK cells present in the lung when comparing aerosol PBS + human NK
cell-treated mice versus aerosol IL-2 treated mice and when comparing aerosol
PBS + NK cell--treated mice versus aerosol IL-2 + human NK cell-treated mice
(P = 0.1 and P = 0.23, respectively). NK cells are known to release a variety of
cytokines and immune stimulators, such as INF and MIP-1 , both of which are
potent macrophage activators [17]. Activated monocytes/macrophages can
themselves secrete cytokines that activate NK cells [17]. There is a possibility
that the injected human NK cells activate the mice’s monocytes/macrophages,
which would in turn stimulate the mice’s own NK cells. There was no significant
difference in the amount of mouse NK cells inside the lung metastasis when we
compared aerosol IL-2 versus aerosol IL-2 + human NK cell treated mice (P =
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0.2) and when we compared aerosol PBS versus aerosol PBS + human NK cell
treated mice (P = 0.2).

Figure 18. Aerosol IL-2 increased mouse NK cells in lung metastasis. Fluorescent
microscopy was used to determine the NK cell infiltration in the lung using anti-mouse
NKp46 (red). Cellular nuclei were identified with Hoechst33258 (blue). Mean positive
fluorescence was quantified using the Simple PCI software in 5 random fields per
section. P < 0.05 was considered significant.
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SUMMARY
We have demonstrated that aerosol IL-2 increases the number of NK cells
inside pulmonary osteosarcoma metastasis. This explains why combining NK cell
therapy with aerosol IL-2 increases its effectiveness against osteosarcoma lung
metastasis. A larger number of injected NK cells come into contact with their
target tumor, increasing apoptosis and thus reducing lung metastasis. We have
also demonstrated that aerosol IL-2 increases the number of mouse NK cells
inside the tumor nodules. Whether direct killing of the human tumor cells by
mouse NK cells contributes to aerosol IL-2’s therapeutic efficacy is a matter of
debate. Mouse NKG2D and human NKG2D recognize different ligands, with
limited amino acid sequence homology among them [60]. However, even if
mouse NK cells aren’t directly responsible for the killing, they can still be
activated by human IL-2 [72]. Consequently, they might in turn secrete other
immune activating cytokines. For example, IL-2 activated NK cells secrete INF ,
TNF , MIP-1

, and GM-CSF, all of which stimulate macrophages [16].

Activated macrophages may be responsible for attacking the osteosarcoma cells.
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RESULTS

Chapter 7
Aerosol IL-2 + NK cell therapy increased the overall survival of mice with
osteosarcoma lung metastasis
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RATIONALE

We have demonstrated that aerosol IL-2 + NK cell therapy reduces
pulmonary metastatic burden, as measured by a decrease in tumor numbers and
size, as well as an increase in tumor apoptosis. One of the main goals for this
investigation was to provide pre-clinical data to support moving forward with a
clinical trial. To further test aerosol IL-2 + NK cell’s potential as a therapeutic, we
designed a study to determine whether treatment with aerosol IL-2 + NK cells
increases overall survival.
3 million LM7 cells/mouse were injected intravenously through the tail vein
of nu/nu mice. Once micro-metastasis was confirmed, treatment was initiated
with aerosol PBS, aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK cells
and was continued for 5 weeks. Aerosol treatment was given 3 times per week.
50 million human NK cells/mouse were injected through the tail vein 2 times per
week. We then proceeded to determine the overall survival for the mice in the
four treatment groups. We ended the survival study 162 days after starting
treatment. Mice that had survived until this moment were euthanized. Long term
survival was assessed from the first day of treatment until death.
RESULTS
Aerosol IL-2 + NK cells increased the overall survival of mice with
osteosarcoma lung metastasis

55

Aerosol IL-2 + NK cell therapy significantly increased the overall survival
of mice with osteosarcoma lung metastasis (Figure 19B). Mice treated with
aerosol PBS had a median survival of 71 days, while aerosol IL-2 + NK cell
treated mice had a median survival of 130 days (P = 0.0153). By day 94 all the
control mice were dead. 40% of the aerosol IL-2 + NK cell treated mice survived
to the end of the study.
Treatment with aerosol IL-2 also increased the survival of mice with
osteosarcoma lung metastasis (Figure 19C). Aerosol IL-2 increased the median
survival from 71 days to 89 days (P = 0.03). Three aerosol IL-2-treated mice
survived until the end of the study. The median survival of aerosol PBS + NK celltreated mice was 109.5 days, higher than either the median survival of aerosol
IL-2-treated or aerosol PBS-treated mice. Yet, because 3 aerosol PBS + NK celltreated mice died very early in the study, the increase in overall survival was not
significant when compared to control (P = 0.06; Figure 19D).
The median survival of mice treated aerosol IL-2 + NK cells was higher
than those treated with aerosol IL-2 (Figure 19E) and those treated with aerosol
PBS + NK cells (Figure 19F). However, the difference in overall survival was not
significant (P = 0.7, P = 0.57, respectively). This was due to the increased lifespan provided by aerosol PBS + NK cells and aerosol IL-2 treatment, though not
as much as that provided by aerosol IL-2 + NK cells therapy.
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Figure 19. Effect of aerosol IL-2, NK cell therapy, and aerosol IL-2 + NK cells on
the overall survival of mice with osteosarcoma lung metastasis. Nude mice were
injected intravenously with LM7 cells. Therapy was initiated 6 weeks later and
continued for 5 weeks. Mice were euthanized when they became moribund or after
162 days. a. Long-term survival was assessed from the first day of treatment. Overall
survival of mice treated with aerosol IL-2 + NK cells (b), aerosol IL-2 (c) and aerosol
PBS + NK cells (d) were compared to with those of aerosol PBS-treated mice. The
overall survival of mice treated with aerosol IL-2 + NK cells was also compared with
that of mice treated with aerosol IL-2 alone (e) or aerosol PBS + NK cells (f). The logrank test was used to determine statistical significance. P < 0.05 was considered
significant

As demonstrated in Figure 20, most of the mice that survived for 162 days
did not have any visible metastasis present. Only one lung demonstrated the
presence of metastasis. It belonged to a mouse treated with aerosol IL-2. This
mouse only had one metastatic nodule with a diameter of less than1.3 mm. This
demonstrates that treatment with aerosol IL-2, aerosol PBS + NK cells or aerosol
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IL-2 + NK cells not only decreased tumor burden and increased survival, but
were also capable of eliminating metastasis. We could say that macroscopically,
40% of the mice treated with aerosol IL-2 + NK cells were cured of the
malignancy, while 30 % of the mice treated with aerosol PBS + NK cells and 20%
of the mice treated with aerosol IL-2 were cured of malignancy.

Aerosol IL 2

Aerosol PBS
+ NK Cells

Aerosol IL 2 +
NK Cells

Figure 20: Representative picture of lung harvested from treated mice that
6
were alive at the end of the study. Nude mice were injected i.v. with 3X10 LM7
cells. Therapy was initiated 6 weeks later. Mice were treated with aerosol IL-2,
aerosol PBS + NK cells or aerosol IL-2 + NK cells for five weeks. Long-term
survival was assessed from the first day treatment was initiated. Mice were
euthanized when they became moribund and after 162 days.

SUMMARY
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Our results demonstrate that aerosol IL-2 + NK cell therapy significantly
increased the survival of mice with osteosarcoma lung metastasis. Treatment
with aerosol IL-2 also significantly increased survival. However, the increase was
less significant and to a lesser degree. Aerosol IL-2 + NK cell therapy increased
the median survival from 71 days to 132 days. This median survival was higher
than the survival seen in the other 2 treatment groups, though the difference was
not significant. 40% of mice treated with aerosol IL-2 + NK cells survived the
study at 162 days, with no macroscopic evidence of disease. 30% of mice
treated with aerosol PBS + NK cells survived for 162 days, with no macroscopic
evidence of disease. 30% of the mice treated with aerosol IL-2 survived for 162
days, with one of the mice demonstrating macroscopic evidence of disease. All
the control mice had died by day 94.
The survival of the mice treated with aerosol IL-2 + NK cells was higher
than that of the mice treated with aerosol IL-2 or NK cells alone. However, the
difference in survival was not statistically significant. This was due to the ability of
monotherapy with either aerosol IL-2 or NK cells to increase survival. In order to
observe significance between the overall survivals between these treatment
groups, a future experiment would be developed in which we extend the survival
study beyond 162 days. As demonstrated in Figure 20, none of the lungs of the
surviving mice treated with aerosol IL-2 + NK cells had evidence of macroscopic
disease, while one mouse treated with aerosol IL-2 alone had macroscopic
disease in the lung. In all probability, this mouse would have died if the study had
been extended. A true survival study would be waiting until all of the mice in
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each treatment group died, or until we could establish significant difference
between the groups. If statistical significance could not be established, we would
repeat the experiment starting treatment at earlier or later time points. The
effectiveness of NK cell therapy is dependent on tumor size. Choosing a different
time point to start treatment would mean treating lung nodules of greater or
smaller sizes. This can translate into finding the difference in therapeutic efficacy
between the three treatment modalities.
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Chapter 8
Toxicity of aerosol IL-2 therapy
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RATIONALE
One of the main reasons behind the use of aerosol IL-2 is to avoid the
toxicities associated with systemic IL-2 treatment. The safety of aerosol IL-2 has
been well documented in clinical trials [52, 55, 73]. Reversible airway irritation
that causes non-productive coughing has been documented as the dose-limiting
toxicity for aerosol IL-2 [55]. This side effect is much more tolerable compared to
the high grades fevers, malaise, and fatigue normally associated with IL-2
treatment. In addition, it does not have the potential for the development of
vascular leak syndrome, which has been reported to have caused respiratory
failures in certain cases [74]. Patients report a much better quality of life,
compared to systemic IL-2 treatments [52]. This lack of systemic toxicities is
associated to very low IL-2 serum increases observed during aerosol treatment,
with IL-2 levels peaking to just 1% of those observed after i.v. bolus injections
[55, 75].
In this chapter, we describe how we evaluated aerosol IL-2 toxicity. Both
Nu/Nu and BALB/C mice were used. BALB/C mice were used because of their
immunocompetence. The lack of T-cells in Nu/Nu mice makes this model
insufficient to represent aerosol IL-2-indued side effects. Nu/Nu mice had to be
used to investigate NK cell associated toxicities because immunocompetent mice
reject human NK cells.
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RESULTS
Aerosol IL-2 does not cause acute or chronic toxicities in
immunocompetent mice as evaluated by histological examination
BALB/C mice were treated with either aerosol IL-2 or aerosol PBS every
other day for one week. Mice were sacrificed three days and one week after the
start of the aerosol treatment to investigate acute toxicity. They were also
sacrificed one month after the end of treatment. Lungs, spleens, livers, hearts
and kidneys were fixed in formalin and embedded in paraffin. Corresponding
H&E stained slides were analyzed with the help of Dr. John Stewart (Department
of Pathology, MD Anderson Cancer Center). We did not find any histological
evidence for acute or chronic inflammation, scarring or toxicity in the lungs,
spleen, liver, heart or kidney of either the aerosol PBS or aerosol IL-2 treated
mice (Figure 21).
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Figure 21: Aerosol IL-2 does not cause acute or chronic inflammation, scarring or
toxicity. Representative H&E stained slides of lung, spleen, liver, heart and kidney of
BALB/C mice treated with aerosol PBS or aerosol IL-2 for one week. Mice were euthanized
either three days or one week after start of treatment, or one month after the end of
treatment. Pictures shown were obtained from those mice sacrificed one month after the end
of treatment. Figure and figure legend were originally published in Pediatric Blood and
Cancer 2013. This material is reproduced with permission of John Wiley & Sons, Inc..

Aerosol IL-2, NK cell therapy or aerosol IL-2 + NK cell therapy does not
cause acute or chronic toxicities in nu/nu mice as evaluated by histological
examination
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Nu/Nu mice were treated for one week with aerosol PBS + NK cells or
aerosol IL-2 + NK cells. Mice were euthanized one day, three days and one week
after NK cell injection. Lungs, spleens, livers, hearts and kidneys were stained
with H&E and analyzed with the help of Dr. John Stewart (Department of
Pathology, MD Anderson Cancer Center). No histological evidence of acute
inflammation, scarring or toxicity was found. Nu/Nu mice with LM7 metastasis
were treated with aerosol PBS, aerosol IL-2, aerosol PBS + NK cells and aerosol
IL-2 + NK for 5 weeks. Mice were euthanized at the 5th week after start of
treatment. Lungs, spleens, livers, hearts and kidneys were stained with H&E and
analyzed with the help of Dr. John Stewart (Department of Pathology, MD
Anderson Cancer Center). No histological evidence of chronic inflammation,
scarring or toxicity was found.
Aerosol IL-2 therapy does not alter complete blood count or liver enzyme
chemistry
The complete blood count [CBC] of mice with LM7 metastasis that had
been treated with aerosol IL-2 or aerosol PBS for two and five weeks was
determined (Figure 22 A, B). Aerosol IL-2 therapy did not alter CBC values. This
suggests that aerosol IL-2 does not produce a significant systemic inflammation.
Liver enzyme chemistry levels of the same mice treated for five weeks were also
examined (Figure 22C). No significant changes in liver enzyme chemistry were
found, suggesting aerosol IL-2 does not induce liver damage. Alkaline
phosphatase was increased in aerosol PBS and aerosol IL-2 treated mice when
compared to normal mouse basal levels. This was expected because alkaline
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phosphatase levels are increased in patients with osteosarcoma, and is
associated with worse prognosis [76].

A

B

C

Figure 22: Aerosol IL-2 does not alter CBC or Liver Enzyme Chemistry:
Mice were treated with aerosol PBS or aerosol IL-2 for 2 (A) or 5 weeks (B)
and their CBC was determined. C. Liver enzyme chemistry was determined
after 5 weeks of treatment. Basal mouse levels for CBC and liver enzyme
chemistry are shown. P< 0.05 was considered significant.
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Serum IL-2 levels following aerosol IL-2 treatment
Serum IL-2 levels were measured in mice treated with aerosol IL-2
2 times per week for 2 and 5 weeks. Aerosol PBS treatment was used as the
negative control. The positive control was serum from mice treated with a single
dose of 20,000U IL-2 i.p, the dose normally used in therapeutic studies
evaluating adoptive cellular therapy [77]. Aerosol IL-2 given for 2 weeks did not
significantly increase serum IL-2 levels compared to aerosol PBS (P = 0.3). While
aerosol IL-2 given for 5 weeks resulted in mild elevations in serum IL-2
(P=0.012), these levels were significantly lower than the IL-2 levels measured in
mice treated with a single dose of 20,000 U IL-2 i.p. (Figure 23) (Originally
published in Pediatric Blood and Cancer 2013. This material is reproduced with
permission of John Wiley & Sons, Inc.) These very low increases in serum IL-2
caused by aerosol IL-2 explain the lack of systemic side effects associated with
aerosol IL-2, as well as the fact that aerosol IL-2 therapy did not increase the
number of injected human NK cells in extra-pulmonary organs. It further
strengthens the argument that aerosol IL-2 therapy is localized and organspecific.
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Figure 23: Serum IL-2 levels after aerosol IL-2 treatment: ELISA was used to determine
serum IL-2 for mice treated with aerosol PBS, aerosol IL-2 for 2 weeks, aerosol IL-2 for 5
weeks and 1 dose of 20,000U IL-2 i.p. P < 0.05 was considered significant. Figure and figure
legend were originally published in Pediatric Blood and Cancer 2013. This material is
reproduced with permission of John Wiley & Sons, Inc..
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Neither aerosol IL-2 nor NK cell therapy induces weight change in mice
To further corroborate that aerosol IL-2 is non-toxic, we monitored the
weight of mice with LM7 lung metastasis treated for five weeks with either
aerosol PBS, aerosol IL-2, aerosol PBS + NK cells, or aerosol IL-2 + NK cells.
Weight change was monitored from the moment the treatment was initiated to
one week after the treatment was stopped. As a control, we also monitored the
weight change of a group of similarly aged mice for a period of 6 weeks. All mice
experienced weight gain during a period of 6 weeks. However, there was no
significant difference between the weights gained by the 5 groups (Figure 24).
The mice that had no metastasis and received no treatment, gained an average
of 2.07 g ± 0.6. This weight gain is not significantly different from the average
weight gained by those with metastasis and treated with aerosol PBS (1.6 g ±
0.93; P = 0.748), aerosol IL-2 (2.62 g ± 0.8, P = 0.564), aerosol PBS + NK cells
(2.47 g ± 1.37, P = 0.773) and aerosol IL-2 + NK cells (2.6 g ± 0.565; P = 0.96).
In addition, the weight gain experienced by aerosol PBS treated mice was not
significantly different from that experienced by mice treated with aerosol IL-2 (P =
0.4), aerosol PBS + NK cells (P = 0.6) and aerosol IL-2 + NK cells (P = 0.4).
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Figure 24. Weight gain during treatment. The weights of mice with LM7 metastasis
and treated with aerosol PBS, aerosol IL-2, aerosol PBS + NK cells and aerosol IL-2 +
NK cells for 5 weeks were monitored. The weight of untreated mice without lung
metastasis was monitored as a control. P<0.05 was considered significant.
SUMMARY
In this chapter we established the safety of aerosol IL-2 therapy, NK cell
therapy and aerosol IL-2 + NK cell therapy. Histological examination of the
spleen, lung, liver, heart and kidney of mice treated with aerosol lL-2, aerosol
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PBS + NK cells or aerosol IL-2 + NK cells showed no signs of acute or chronic
inflammation, scaring, or toxicity. There weren’t any treatment associated weight
changes. Furthermore, aerosol IL-2 treatment did not alter the complete blood
count or the liver enzyme chemistry. This establishes that aerosol IL-2 treatment
is organ specific and does not induce an altered systemic inflammatory state.
Systemic IL-2 is known to be able to cause leukopenia and rebound
lymphocytosis [78], neither of which was suggested by the complete blood count.
Other toxicities associated with systemic IL-2 that could be represented by a
complete blood count include thrombocytopenia and anemia [79]. In addition, IL2 can cause hepatic toxicity [79], which would present as increased serum liver
enzymes. We also established that aerosol IL-2 can cause a small but significant
increase in serum IL-2 levels if given for 5 weeks every other day. However,
these levels are below those found in mice treated with intraperitoneal IL-2. This
explains the lack of systemic side effects associated with aerosol IL-2 treatment
and the reason why aerosol IL-2 increased NK cell numbers in the lung, but not
in other organs. This suggests aerosol IL-2 activity is organ-specific.
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Chapter 9
Discussion: Implications of Results and Future Directions
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The 5-year survival rate for patients with osteosarcoma has plateaued at
60-70% using combination chemotherapy and surgery. With the exception of LMTP-PE, no new drugs have been developed for either newly diagnosed or
relapsed osteosarcoma in 20 years [10]. The primary cause of death is
respiratory failure due to metastatic burden [2], as the lung is the most frequent
site of metastatsis. Lung osteosarcoma metastasis has a very bad prognosis,
with a 5 year survival of 33% [5]. Survival is even lower for relapsed patients.
Less than 20% of relapse patients survive [6]. Moreover, salvage chemotherapy
following relapse has been shown to slow disease progression but has no impact
on long-term survival [80]. This implies the development of chemotherapy
resistance. For this reason, we must look beyond traditional chemotherapeutics
for the treatment of primary and recurrent osteosarcoma lung metastasis.
As mentioned before, L-MTP-PE is the first new agent approved for the
treatment of osteosarcoma in the last 20 years [10]. Adding L-MTP-PE to
standard chemotherapy for primary osteosarcoma increases the 6-year survival
from 70 to 78% [9]. L-MTP-PE activates the tumoricidal properties of pulmonary
macrophages and peripheral blood monocytes. The success of L-MTP-PE in
increasing survival paves the way for the development of other immunotherapies
to target osteosarcoma lung metastasis. Our laboratory previously showed that
the intravenous injection of IL-11R -CAR+ T-cells resulted in the regression of
osteosarcoma lung metastases in a nude mouse model [11]. These findings
further support the potential benefit of immunotherapy in the treatment of this
malignancy. One of the drawbacks of IL-11R -CAR+ T-cell therapy is the
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collateral organ toxicity to those organs that express the IL-11 R . IL-11 R is
expressed in the liver, stromal tissues of the GI tract, surface and gland epithelial
cells, and on endothelial cells. By contrast, NK cells are a component of the
innate immune system that recognize and kill malignant and virally infected cells
but not normal host cells. Therefore the therapeutic: toxicity index is expected to
be much higher.
NKG2D ligand expression in osteosarcoma
NKG2D ligands were highly expressed in both osteosarcoma cell lines
(Figure 1) and patient tumor specimens (Figure 4). NKG2D is the major
activating receptor on NK cells. The NKG2D ligand status determines the
effectiveness of NK-cell based immunotherapies [58, 62]. These results suggest
that osteosarcoma is a good target for NK cell therapy. Among the patient
samples, a greater percentage of cells expressed NKG2D ligands in pulmonary
metastases (77%) than in the primary tumors (57%). This validates the potential
of NK cell therapy for relapsed disease in the lungs. NK killing assays further
corroborated osteosarcoma’s susceptibility to NK cells. It also demonstrated that
the magnitude of in vitro killing correlated with the levels of NKG2D ligand
expression (Figure 2). With the exception of KRIB cells, NK cytotoxicity against
human osteosarcoma cells was 40 -50% at 1:1 E:T ratios. NK cytotoxicity against
KRIB cells was near 10% at 1:1 E:T ratios. This reduced cytotoxicity correlated
with the lower expression of NKG2D ligands found on KRIB cells when compared
to the other cell lines (Figure 8). Conversely, NK cytotoxicity was significantly
decreased when the NKG2D- NKG2D ligand interaction was blocked. This
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demonstrates that NK-mediated killing of osteosarcoma is dependent on NKG2D
ligand expression. It also suggests the effectiveness of NK cell therapy could be
predicted based upon the patients’ specific osteosarcoma NKG2D ligand
expression.
Aerosol IL-2 increases NK cells in the lung
One of main purposes of using concomitant aerosol IL-2 was to increase
the number of injected NK cells in the lung in order to facilitate their therapeutic
potential against pulmonary osteosarcoma lung metastasis. We demonstrated
that, while intravenous injection of fluorescent-labeled NK cells resulted in some
localization in the lung, aerosol IL-2 significantly increased the number of NK
cells in the lung three days post-injection (Figure 5). This increased localization
of labeled NK cells was organ specific, as the number of NK cells was not
increased in the liver, spleen, heart or kidney (Figure 6). In both aerosol PBS and
aerosol IL-2 treated mice almost no human NK cells localized in the heart or
kidney, while a very large amount were found present in the liver and spleen.
These data is consistent with studies studying organ distribution of allogeneic NK
cells in human patients [45]. Thirty minutes after transfusion, allogeneic NK cells
aggregate in the lung. Two hours post transfusion they redistribute to the rest of
the body, concentrating in the spleen, liver and bone marrow.
We determined the increase in the number of NK cells in the lung is
caused by an increase in proliferation. Aerosol IL-2 significantly increases the
percentage of proliferating NK cells in the lung (Figure 7), but not in the spleen or
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liver (Figure 9). It slightly increases the proliferation of NK cells in the bone
marrow 24 hours post injection, but not at 72 hours post injection (Figure 8). The
increase in NK proliferation in the lung was greatest 72 hours after injection. This
correlates to the time point in which we see the largest increase of NK cell
numbers in the lung. This shows that the central site for aerosol IL-2 induced
proliferation is the lung. On the other hand, intranasal respiratory virus infection
induces NK proliferation in the bone marrow, not in the lung [71]. The increase of
NK numbers in the lung is a result from migration from the bone marrow.
Aerosol IL-2 does not increase NK cell numbers or proliferation in extra
pulmonary organs because aerosol IL-2 treatment for less than two weeks does
not increase serum IL-2 levels (Figure 27). This suggests that the IL-2 from
aerosol concentrates in the lung, with little spill over to the periphery.
Aerosol IL-2 increased the efficacy of NK cells in vivo
Aerosol IL-2 also increases the number of injected NK cells present in the
metastatic pulmonary nodules (Figure 17). We have already shown that NK
killing of osteosarcoma is dependent on the E: T ratio (Figure 2). Having an
increased presence of NK cells inside the tumor should translate into an
increased therapeutic efficiency. NK-killing is mediated by the release of
cytotoxic granules that trigger the apoptotic pathway [81]. The addition of aerosol
IL-2 to NK cell therapy significantly increased the degree of apoptosis present in
the tumor nodules (Figure 15). These increased levels of apoptosis correlated
with decreased overall metastatic burden, as measured by tumor numbers and
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tumor size (Figure 11- 14). Higher NK cell numbers contributed to increased
tumor apoptosis, which translated into a better therapeutic outcome. However,
aerosol IL-2’s may also improve NK therapy by other mechanisms. IL-2 is known
to increase the expression of NKG2D and NCR receptors. This makes NK cells
more sensitive to activating ligands, which increases cytotoxicity and cytokine
secretion [82]. IL-2 treatment can enhance NK adhesion and killing against weak
targets, i.e., those who express low levels of activating ligands [83]. IL-2 also
enhances F-actin reorganization in NK cells, necessary for cytotoxic granule
release [84]. Aerosol IL-2 could have also increased the NK therapeutic efficacy
by directly enhancing cytotoxicity in addition to increasing their proliferation.
Aerosol IL-2 also increased the number of mouse NK cells in metastatic
pulmonary nodules (Figure 18). Whether this contributed to the therapeutic
outcome is unknown. Monotherapy with aerosol IL-2 significantly increased
tumor apoptosis (Figure 15). It also decreased tumor number and tumor size
(Figure 11-14), though not significantly. However, it did increase mean survival
(Figure 20). Mouse NKG2D and human NKG2D recognize different substrates,
and there is little sequence homology among these [60]. It is unlikely that the
observed increased tumor apoptosis was due to direct killing by mouse NK cells.
However, mouse NK cells can be activated by human IL-2 [85]. Activated NK
cells are known to secrete a variety of cytokines that influence other members of
the immune system. For example, they release potent macrophage activators,
such as INF and MIP-1 [17]. They can also kill M0 and M2 macrophages, but
spare M1 macrophages [86]. This may suggest that IL-2 activated mouse NK
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cells could have increased tumor apoptosis by enhancing the tumoricidal
properties of the macrophage population in the lung. NK cells also interact with T
cells and dendritic cells [16], but this interaction is not relevant in our
investigation because our mouse model was athymic. NK cells are also able to
kill endothelial cells [87]. The vasculature present in LM7 osteosarcoma
metastasis is of mouse origin. Mouse tumor vasculature expresses NKG2D
ligands [88]. This implies that tumor apoptosis could have been increased by a
reduced blood flow caused by mouse NK-mediated killing of tumor vasculature.
Aerosol IL-2 + NK cell therapy increased overall survival
The enhanced tumor regression conferred by aerosol IL-2 + NK cell
therapy rendered an increase in overall survival in mice with osteosarcoma lung
metastasis (Figure 19B). Surprisingly, we also observed that monotherapy with
aerosol IL-2 increased overall survival (Figure 19C). This may be due to an
indirect activation of other immune cells in the lung. One plausible candidate may
be an increased activation of lung macrophages. As we explained above, IL-2activated mouse NK cells may have induced the polarization of macrophages
into M1. Aerosol PBS + NK cell therapy also increased survival. However this
increase in survival was not statistically significant. This was due to variability in
the therapeutic efficacy seen with aerosol PBS + NK cell therapy. Some mice
died early in the survival study, while others had an extended life-span. This
suggests that the addition of aerosol IL-2 to NK cell therapy confers consistency
in terms of its therapeutic effect.
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Aerosol IL-2 Toxicity
One of the reasons we decided to use aerosol IL-2 to expand NK cells in
the lung was to avoid the toxicities associated with systemic IL-2. IL-2 can cause
a myriad of toxicities, including oliguria, hypotension, elevated liver enzymes,
thrombocytopenia, and capillary-leak syndrome, which can lead to fluid retention,
adult respiratory distress syndrome and myocardial infarction [49]. Histological
examination of the lungs, spleen, liver, kidney and heart did not reveal any
evidence of acute or chronic inflammation, edema, scarring, or other organ
damage (Figure 21). CBC and serum enzyme levels were all within normal limits
(Figure 22). There wasn’t any weight associated changes in mice treated with
aerosol IL-2, aerosol PBS + NK cells or aerosol IL-2 + NK cells (Figure 24).
Serum IL-2 levels following aerosol IL-2 therapy were well below those found in
mice treated with intraperitoneal IL-2 (Figure 23). This explains the lack of
toxicity. This suggests that aerosol therapy concentrates IL-2 in the lung,
specifically activating the proliferation of the infused human NK cells in the lung
(Figure 7), with very minimal spill-over into the periphery. This translates into the
absence of systemic toxicities as well as the absence of IL-2-induced NK growth
in the liver and spleen (Figure 9), and the minimal activation seen inside the bone
marrow (Figure 8). Our results are consistent with clinical trials using aerosol IL2, which demonstrate minimal toxicities [50, 51] and improved quality of life when
compared to systemic IL-2 therapy [52].
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Limitations of Study
We used human NK cells for our experiment partly due to the difficulty of
isolating and expanding mouse NK cells ex vivo. For this reason, we used
human osteosarcoma LM7 metastasis in a nude mouse model for our in vivo
studies. Since nude mice do not have T cells, this had the added benefit of
limiting any results demonstrating therapeutic effect to the interactions between
aerosol IL-2, NK cells and the target tumor. However, the model does not present
a complete picture of what would happen clinically. IL-2 is a potent activator of
both cytotoxic T cells and regulatory T cells, of which the former may have a
positive effect on therapy, while the later might limit it. Also, the model does not
take into account the co-stimulatory relationships between cytotoxic T cells and
NK cells [16], which could influence the effect of aerosol IL-2 + NK cell therapy.
The lack of T cells may limit an accurate picture of the toxicity of aerosol IL-2, as
IL-2 systemic side effects could be attributed to T cell activation. However, we
addressed this concern by treating BALB/C mice with aerosol IL-2 in our toxicity
studies (Figure 21) and finding no histological evidence of acute or chronic
inflammation, scarring or damage in sections of lung, spleen, heart, liver or
kidney.
Conclusion
There is a need for the development of new therapeutics for patients with
osteosarcoma lung metastasis. In the last 20 years, mifamurtide has been the
only new therapeutic that has been approved for the treatment of osteosarcoma
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[10].Our data has shown that the aerosol delivery of IL-2 is an effective way to
induce selective migration and expansion of NK cells in the lungs. Aerosol IL-2
also increased human NK cell numbers within lung tumor nodules and increased
tumor cell apoptosis. This translated into reduced pulmonary metastasis and
increased survival. Combining aerosol IL-2 therapy with NK cells increased the
therapetic efficiency of NK cell therapy without causing systemic toxicity. Since
the safety and tolerability of aerosol IL-2 have already been documented in
several different clinical trials [50, 51], this organ-specific cytokine delivery
concept can be exploited to target selective NK cell migration, expansion, and
activation in the lung. This combination therapy can therefore serve as a new
therapeutic approach for patients with relapsed and unresponsive osteosarcoma
lung metastases.
FUTURE DIRECTIONS
Translation into Clinical Trials
One of the main purposes of this investigation was to provide pre-clinical
data testing a novel therapeutic approach for the treatment of osteosarcoma lung
metastasis with the possible goal of moving forward with a clinical trial. Currently
a Phase I/II clinical trial is being run in MD Anderson with the purpose of
determining the highest tolerable dose of aerosol IL-2 and its safety in the context
of patients with lung metastasis. Among those to be treated with aerosol IL-2 are
patients with osteosarcoma lung metastasis. Dr. Nancy Gordon (Division of
Pediatrics, The University of Texas MD Anderson Cancer Center) from Dr.
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Kleinerman’s laboratory is coordinating this effort. Serum concentrations of IL-2
will be reported to determine if any peripheral spill-over occurs. Peripheral
absolute lymphocyte counts will also be recorded. Early lymphocyte recovery
after chemotherapy has been associated with improved prognosis in pediatric
patients with osteosarcoma [89]. We would attempt to correlate the effectiveness
of aerosol IL-2 therapy with absolute lymphocyte counts. Lung tumor biopsies
would be collected before and after aerosol IL-2 treatment. Using
immunohistochemistry, we will determine if aerosol IL-2 increases NK cell
infiltration within the patient lung nodules and we will correlate this data with the
degree of apoptosis and/or necrosis within the metastatic nodules. If any
objective response is observed in this clinical trial, we would want to determine if
it correlates with increased NK cell tumor infiltration and tumor apoptosis. Any
positive correlation would give impetus to moving forward with a Phase I clinical
trial examining the use of aerosol IL-2 and NK cell therapy.
The purpose of a phase I clinical trial involving the use of aerosol IL-2 +
NK cells will be to determine the highest tolerable dose and safety of ex vivo
expanded [39] allogeneic KIR-mismatched NK cells given in combination with
aerosol IL-2 therapy in the context of patients with osteosarcoma lung
metastasis. The dose of aerosol IL-2 to be given would be determined by the
above mentioned clinical trial. To our knowledge, there have been no
investigations that have reported a peak tolerable dose for infused NK cells. The
highest dose of NK cells to have been infused into patients has been 4.7 × 1010 ±
2.1 × 1010 ex vivo expanded autologous NK cells. No toxicities were reported in
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this study [37]. The most toxic adverse effects associated with NK cell infusions
have been Grade I and II pruritus, rigors and muscle aches using 2 X 107/kg NKenriched KIR mismatched cells [90]. In our investigation we injected 5 X 107 NK
cells per mouse two times per week for 5 weeks. Considering nu/nu mice weigh
between 20 and 30 grams, the corresponding NK cell dose should be between
1.7 X 109 - 2.5 X 109 NK cells/kg for a human patient 2 times per week for 5
weeks. Since such high numbers of NK cells have never been infused into
patients before, a gradual increase in NK cell infusions should be attempted in
order to determine the highest tolerable dose. Patients would be treated with NK
cell therapy with or without concomitant aerosol IL-2. Therapeutic effect, as well
as possible NK toxicities, could be exacerbated by the addition of aerosol IL-2. If
throughout the trial we observe that the addition aerosol IL-2 confers an
additional therapeutic benefit, we would add aerosol IL-2 to those patients
receiving NK cell therapy alone. Tumor biopsies would be obtained as well as
blood samples before and after treatment. We would want to determine the
degree of NK tumor infiltration as well as tumor apoptosis. We would want to
determine if increased NK tumor infiltration, increased absolute lymphocyte
counts and increased peripheral NK cells correlate with increased tumor
apoptosis and with objective response, if any is seen.
After determining the highest tolerable dose and the safety of NK cell
therapy, a Phase II clinical trial would be designed. If a peak tolerable dose of NK
cells cannot be established, then the dose to be used in this trial will correspond
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to the dose associated with the highest objective response and/or with the
highest degree of tumor apoptosis.
As demonstrated by killing assays (Figure 2), NK cell cytotoxicity
increases with increasing E:T ratio. An E:T of at least 5 is required for maximum
efficiency. To increase therapeutic efficiency, a Phase II clinical trial should be
designed so that aerosol IL-2 + NK cell therapy is given in the context of minimal
residual disease (MRD) or after the surgical excision of the metastatic lesions.
We would not expect NK cell therapy to successfully destroy a bulky tumor with a
large surface area. We believe NK cell therapy would be more effective against
microscopic metastatic foci. Treatment duration would be dependent on the
Phase I trial that is currently being undertaken to determine the safety of aerosol
IL-2 therapy and our envisioned Phase I trial that would determine the highest
tolerable dose of NK cells given in combination with aerosol IL-2. We hope that
aerosol IL-2 + NK cell therapy will increase the 5-year survival of patients with
osteosarcoma lung metastasis beyond 33% [5].
Soluble NKG2D ligand concentration in patients with osteosarcoma
Our data for patient specimens demonstrated that NKG2D ligand
expression was higher in osteosarcoma lung metastasis than in primary tumors
(Figure 4). This seems to be counterintuitive in terms of evasion from NK
immunosurveillance. Decreased expression of NKG2D ligands on colorectal
cancer correlates with tumor stage progression, with the lowest expression
associated with stage IV [91]. One of the mechanisms by which tumors with
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elevated NKG2D ligand expression can evade NK recognition is by shedding
NKG2D ligands. Indeed, serum soluble MICA is increased in metastasis [92]. In
melanoma, elevated serum soluble ULBP2 levels correlate with a poorer
prognosis [93].
To asses if osteosarcoma lung metastasis is associated with increased
NKG2D ligand shedding, we would measure the serum concentration of soluble
NKG2D ligands in patients with osteosarcoma lung metastasis and compare
these values to serum concentrations from patients with primary osteosarcoma
and health patient serum. We would corroborate these data with in vitro studies
measuring the concentration of soluble NKG2D ligands in the culture media from
human osteosarcoma cells. We would compare the secretion of NKG2D ligands
by osteosarcoma cell lines derived from patient pulmonary metastasis and the
secretion by cell lines derived from primary osteosarcoma. If the results
demonstrate that osteosarcoma metastasis increases soluble NKG2D ligand
expression, this could explain how metastatic osteosarcoma cells evade NK
immunosurveillance even when they have high surface expression of NKG2D
ligands.
Matrix Metalloproteinase 9 (MMP9) is responsible for MICA shedding in
osteosarcoma. Inhibiting MMP9 prevents MICA shedding and increases
osteosarcoma susceptibility to NK cytotoxicity [94]. We hypothesize that the
addition of a MMP9 inhibitor would enhance NK cell therapy against
osteosarcoma lung metastasis. To test this hypothesis we would first chose a
human osteosarcoma cell line derived from a patient with pulmonary metastasis
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capable of secreting high levels of soluble MICA. LM7 would not necessarily
secrete high levels of soluble MICA because it was derived from the primary
human osteosarcoma cell line SAOS-2 after becoming metastatic by passage
through the lungs of Nu/Nu mice [64]. The ability to secrete soluble human
NKG2D ligands would not have provided LM7cells with a survival advantage in a
tumor micro-environment with mouse NK cells because mouse NKG2D does not
recognize human NKG2D ligands [60]. Once we confirm metastasis, we would
treat these mice with NK cells that have been expanded ex vivo with IL-2 and
genetically modified K562 with membrane-bound IL-21 and IL-15 [39] in
combination with or without a MMP9 inhibitor. We would use mice treated with
MMP9 inhibitor alone or without treatment as negative controls. Since ex vivo
expansion growth increases NK cytotoxicity, numbers and life-span, we might not
discover any increased therapeutic effect by the addition of MMP9 inhibitors.
Increased cytotoxicity and increased NK life-span may overcome the inhibitory
effect mediated by soluble NKG2D ligands. To corroborate this, we would repeat
this experiment with freshly isolated NK cells. Since aerosol IL-2 increases NK
cell proliferation in the lung, we would also want to determine if combination NK
cell and aerosol IL-2 treatment can overcome any inhibition provided by soluble
NKG2D ligands. We would design an experiment similar to the one described
above with the addition of aerosol IL-2 to the NK cell therapy. If the addition of
MMP9 inhibitor does not significantly improve the therapeutic efficacy of aerosol
IL-2 + NK cell therapy, but does improve therapeutic efficacy when added to
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aerosol PBS + NK cell therapy, we may be able to conclude that co-treatment
with aerosol IL-2 overcomes the inhibition that is induced by MICA shedding.
Pharmacological upregulation of NKG2D ligands
If aerosol IL-2 + NK cell therapy is to be used in clinical trials, we should
consider the fact that a substantial number of patients with osteosarcoma lung
metastasis have been exposed to chemotherapeutical agents. Chemotherapy
may alter the NKG2D ligand expression in osteosarcoma lung metastasis.
However, since NKG2D ligands are upregulated in response to cellular stress
[23], chemotherapy may actually aid NK cell therapy.
Cisplatin, doxorubicin, and high-dose methotrexate with leucovorin are the
standard chemotherapeutical agents used against osteosarcoma lung metastasis
[6]. Doxorubicin has been shown to increase NKG2D ligand expression on
multiple myeloma cells and to enhance their susceptibility to NK cytotoxicity [95].
To determine if the standard chemotherapy used against osteosarcoma
increases NKG2D ligand expression, we would obtain patient specimens from
osteosarcoma lung metastasis before and after chemotherapy and we would
then do immunohistochemistry staining for NKG2d ligands. We would
supplement these data with in vitro studies comparing the NKG2D ligand
expression of osteosarcoma cells before and after treatment with the above
mentioned chemotherapeutical agents. NK killing assays would also be
performed to determine if chemotherapeutic treatment of osteosarcoma cells
enhances NK killing. If our in vitro data and our patient sample data demonstrate
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that standard chemotherapy against osteosarcoma lung metastasis increases the
expression of NKG2D ligands, we should consider giving NK cell therapy shortly
after chemotherapy has been administered to patients.
We could also investigate alternate chemotherapeutical agents that would
enhance osteosarcoma NKG2D ligand expression and potentially enhance NK
cell therapy. For example, our laboratory has successfully demonstrated that
aerosol gemcitabine treatment of osteosarcoma lung metastasis significantly
inhibits its growth and increases tumor Fas expression [96-98]. Gemcitabine is
known to increase the expression of MICA/B in hepatocellular carcinoma and to
also increase their susceptibility to cytokine-activated killer cells [99]. We would
design an investigation in order to determine if gemcitabine increases the
expression of NKG2D ligands in osteosarcoma and if this translates into a
greater therapeutic efficacy when using NK cell therapy. First, we would
determine if gemcitabine increase NKG2D ligands in vitro on various
osteosarcoma cell lines. Next, we would determine if the expression of NKG2D
ligands in osteosarcoma lung metastasis from mice treated with aerosol
gemcitabine is increased. We could use a Nu/Nu mice model with human
osteosarcoma lung metastasis and/or BALB/C mice model with mouse
osteosarcoma lung metastasis. If we decided to use the BALB/C model, we
would need to test for the expression of mouse NKG2D ligands. If our results
demonstrate gemcitabine-induced NKG2D ligand increase, we would perform a
therapeutic study combining NK cell therapy with aerosol gemcitabine.
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HDAC inhibitors are promising agents with the potential to increase the
expression of NKG2D ligands in cancer. Valproic acid increases the expression
of NKG2D ligands on myeloma [100], ovarian cancer [101], Ewing sarcoma
[102], hepatoma [103], and AML[104], as well as increasing their susceptibility to
NK-mediated cytotoxicity. Valproic acid has also been reported to increase the
expression of MICA/B in osteosarcoma cell, without increasing its soluble form,
leading to an increased susceptibility to NK killing [105]. In our laboratory, we’ve
had great success with the use of another HDAC inhibitor, MS-275. Our
laboratory has shown that MS-275 increases the Fas expression in
osteosarcoma and induces the regression of osteosarcoma lung metastasis
[106-108]. Graduate student Simin Kiany is currently investigating the use of MS275 to increase the expression of NKG2D ligands in osteosarcoma and using it in
combination with NK cell therapy to treat osteosarcoma lung metastasis in a
Nu/Nu mouse model.
Increasing NK homing toward osteosarcoma metastatic nodules in the lung
Aerosol IL-2 increases the number (Figure 5) and proliferation (Figure of
7) of infused NK cells in the lung, leading to increased NK cell retention in tumor
nodules (Figure 16), which in turn increases tumor apoptosis (Figure 14) and
therapeutic efficacy. Yet, a large proportion of infused NK cells still propagate
toward the spleen and liver (Figure 6). Finding a way to increase the retention of
infused NK cells in the lung or to induce their migration from extra-pulmonary
organs could potentially improve the therapeutic efficacy of NK cell therapy. Our
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laboratory has started investigating the role chemokines and chemokine
receptors play in NK cell migration toward tumor locations.
The study of the chemokine receptor CX3CR and its ligands shows great
promise. CXC3CR is a chemokine receptor that is expressed on T cells and
activated NK cells [109]. Pre-clinical studies report that stimulating the
expression of CX3CR ligands causes lung cancer regression. Antitumor activity
was mediated by an increased T cells and NK cell tumor infiltration [110]. The
clearance of YAC-1 cells in the lung of C57BL/6 is mediated by NK cells and is
dependent on the interaction between CXC3CR and the chemokine
CX3CL1[111]. The CXC3CL1/CXC3CR chemokine/receptor axis has also been
implicated in the eradication of neuroblastoma metastases by T cells and NK
cells [112]. Gene therapy using aerosolized liposome encapsulated CX3CL1encoding plasmids significantly reduced mouse osteosarcoma lung metastasis
[113]. We can design a pre-clinical trial in which aerosolized gene therapy with
CX3CL1-encoding plasmids is combined with aerosol IL-2 + NK cells in order to
maximize the killing of osteosarcoma lung metastasis. Aerosol IL-2 would
increase the numbers of NK cells in the lung, while CX3CL1 transduction of
metastatic osteosarcoma cells would enhance the migration of these NK cells
toward the tumor nodules facilitating tumor cell killing. It could also provide the
added benefit of attracting the NK cells that would normally propagate toward the
liver and spleen back toward the tumor sites. For maximum effect, we could
specifically select and expand NK cells with high expression of CXC3CR.
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Another mechanism of exploiting NK chemotaxis toward osteosarcoma
would be to investigate the normal chemokine expression of metastatic
osteosarcoma cell lines. We would then determine which of these chemokines
are more effective in attracting NK cells. We would then selectively isolate and
expand NK cells with these specific receptors for these chemokines from buffy
coats for subsequent adoptive ex-vivo expanded NK cell therapy. Dr. Gangxiong
Huang of Dr. Kleinerman’s laboratory is currently working on this project.
Recently Somanchi et al [114] engineered a way to successfully transfer the
chemokine receptor CCR7 to ex vivo expanded NK cells by incubation with
CCR7-expressing K562s. The plasma membranes of these NK cells acquired
CCR7 via trogocytosis. These NK cells could express CCR7 for 72 hours. This
transient expression of CCR7 successfully enhanced the migration of NK cells
toward the lymph nodes of athymic nude mice. We could select specific
chemokines that are actively expressed in osteosarcoma cells of metastatic
origin. We would design a pre-clinical study in which ex vivo expanded NK cells
are incubated with K562s expressing the chemokine receptor or receptors for
these chemokines. This could potentially enhance the migration of NK cells
toward osteosarcoma metastatic cells in the lung and enhance therapeutic effect.
Exploiting the cross-talk between Macrophages and NK cells
Preliminary unpublished data from our laboratory demonstrates increased
macrophage infiltration of lung osteosarcoma metastasis in Nu/Nu mice treated
with aerosol IL-2. Nu/Nu lack T cells and mouse NKG2D does not recognize
human NKG2D ligands [60]. Increased macrophage infiltration could explain the
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reason we see a therapeutic effect in Nu/Nu mice with human osteosarcoma
metastasis that have been treated with aerosol IL-2 alone. Aerosol IL-2 may
activate mouse NK cells in the lung, and this activated NK cells might
subsequently activate lung macrophages. NK cells are known to secrete a variety
of cytokines that can activate monocytes/macrophages, including INF , TNF ,
MIP-1

, and GM-CSF. Macrophages in turn secrete IL-12 and IL-18 to activate

NK cells [16]. Physical contact between macrophages and NK cells increases the
expression of NKG2D [115]. Activated NK cells have the ability to shift
macrophage polarization toward M1. They do this by killing M0 and M2
macrophages, but sparring M1 macrophages [86]. This suggests an important
role for macrophages in NK-mediated tumor regression.
We could test this hypothesis by first determining the state of polarization
in the macrophage infiltrate of aerosol PBS-treated, aerosol IL-2-treated, aerosol
PBS + NK cell-treated and aerosol IL-2 + NK cell-treated LM7 osteosarcoma lung
metastasis in Nu/Nu mice. Markers for M1 polarization are CD68/HLA-DR, and
those for M2 are CD68/CD163 [116]. If NK-mediated activation of macrophages
to a M1 polarized state is associated with NK-mediated tumor regression, we
would see an increased M1 polarized state in the lung metastasis that have been
treated with aerosol IL-2, aerosol PBS + NK cells and aerosol IL-2 + NK cells
when compared with aerosol PBS treatment. NK cell-macrophage crosstalk is
dependent on both cytokine secretion and physical contact. Human NK cells
might still activate mouse macrophages by the secretion of certain cytokines, but
the activation induced by cell-to-cell contact may be lost. For example, one of the
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ways human macrophages activate human NK cells is by the expression of MICA
[117]. This would not be possible between human NK cells and mouse
macrophages, as mouse macrophages would lack human NKG2D ligands. For
this reason, we may not see much difference in terms of M1 polarization when
we compare aerosol IL-2, aerosol PBS + NK cell and aerosol IL-2 + NK celltreated tumors.
If macrophage activation is important for NK-mediated tumor regression,
we could potentially enhance this regression by the addition of macrophage
activators. As mentioned before, L-MTP-PE has been the only new therapeutic
that has improved survival in osteosarcoma patients [10]. Since L-MTP-PE is a
direct macrophage activator and since NK cells and macrophages can costimulate each other, a combination therapy with aerosol IL-2 + L-MTP-PE + NK
cells could be a novel and effective therapeutic regiment against osteosarcoma
lung metastasis.
Aerosol therapy with other NK activating cytokines
In this investigation we used aerosol IL-2 for the stimulation of NK cells in
the lung due to IL-2’s well known effect on NK cells. However, there are a variety
of other cytokines that are known to stimulate NK cells. IL-15 is another wellknown activator of NK cells and it shares structural similarities with IL-2 [118].
Similar to IL-2, it promotes the survival, proliferation and cytotoxic activity of NK
cells. IL-12 is another cytokine known to activate NK cells, specifically by
stimulating its production of INF-

[119]. Moreover, it has anti-antiangiogenic
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effects specifically modulated through NK cells [120]. However, its capacity to
induce NK proliferation is lower than that of IL-2 or IL-15 [121]. IL-21 can
increase NK cells cytokine productions and cytotoxicity, but in some cases has
been shown to limit their proliferation [17]. IL-15 and IL-21 have the added
benefits of being able to downregulate regulatory T cell numbers [122, 123].
To our knowledge, aerosolized forms of these cytokines have not been
developed. Our lab studied the aerosol gene therapy with PEI: IL-12 in order to
eradicate osteosarcoma lung metastasis, but the aerosol delivery of the actual
cytokine was not evaluated [124]. In theory, if aerosolized forms of these
cytokines were to be developed, we could study their effect on NK recruitment to
the lung and its tumoricidal properties. In vivo experiments would be designed to
compare their capacities to increase injected NK cells in the lung, to increase NK
infiltration of osteosarcoma lung metastasis and their overall ability to enhance
NK cell therapy. In addition, different combinations of these aerosolized would be
evaluated, as studies have shown that they have synergistic effects on NK
activation [118, 125]. The combination of IL-2 and IL-21 is of particular interest,
as IL-21 addition to IL-2 has the capacity to counteract IL-2’s driven regulatory T
cell expansion [123].
Exploring the possible effect of aerosol IL-2 on the stimulation of
regulatory T cells
The inadvertent stimulation of regulatory T cells is of concern for any
therapy involving the use of interleukin-2. Patients receiving IL-2 therapy have
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elevated levels of peripheral regulatory T cells [126]. Regulatory T cells can
specifically inhibit NK cell activity [83, 127]. Low dose IL-2 therapy increases the
proliferation of regulatory T cells in patients with chronic graft-versus-host
disease, with no effect on other CD4+ T cells [128]. This may prove a concern
since our data shows that treatment with aerosol IL-2 for 5 weeks increases
serum IL-2 levels, but to very low levels (Figure 23). Whether or not these levels
would correspond to those that selectively increase regulatory T cells would have
to be determined. Since we used nude mice for our treatment experiments, any
negative effect on therapy that might have been caused by an IL-2 induced
increase in regulatory T cells would not have been apparent.
In order to determine if aerosol IL-2 therapy can increase regulatory T cell
populations, an animal experiment in which immunocompetent mice are given
aerosol IL-2 for at least five weeks would be designed. Treatment for 5 weeks is
essential, since at that time we saw increased serum IL-2 levels. The peripheral
and lung population of regulatory T cells would be monitored from the day before
treatment is started, during the treatment window and afterward. IL-2 serum
levels would also be measured through the study. We would compare the
regulatory T cell population of these mice before the start of treatment and right
after the start of treatment. If there is an increase, we would want to correlate
these numbers with the corresponding values of serum IL-2. We would keep
monitoring regulatory T cell levels after treatment has ended until serum IL-2
levels have returned to normal. We would also want to monitor CD4+T cell levels
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throughout the study, as any increase in regulatory T cell levels might just be
proportional to increases in helper T cell levels.
If we do find an increase in regulatory T cell levels caused by low level
increases of serum IL-2, we would determine if these correlate with decreased
effectiveness of treatment. We would not be able to treat immunocopentnet mice
with ex vivo expanded human NK cells, so the treatment would have to be limited
to aerosol IL-2. We would design a lung metastasis model using BALB/C mice
engrafted with mouse metastatic osteosarcoma cell line K7M3. We would treat
these mice with aerosol PBS or aerosol IL-2 for 5 weeks. We would sacrifice
these mice and extract their lungs at different time points during treatment. We
would measure serum IL-2 levels and regulatory T cell populations at the
moment of euthanasia. Lung tumors would be stained for TUNEL, mouse NK cell
markers and regulatory T cell markers. We would then determine if NK tumor
infiltration and tumor apoptosis decreases with increasing serum IL-2 levels and
regulatory T cell numbers.

Exploring the effect of high dose and low dose IL-2 in the stimulation of NK
cells and its relationship to regulatory T cells
As mentioned above, low-dose IL-2 therapy increases peripheral regulatory T
cells [126] . As figure 23 demonstrates, aerosol IL-2 treatment for 5 weeks can
cause a very low up regulation of serum IL-2. In the setting of immunocompetent
organisms, an upregulation of regulatory T cells could potentially interfere with
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NK cell therapy. To address this concern, we could potentially study the effect of
high and low doses of IL-2 on NK cell cytotoxicity and proliferation, on regulatory
t cells as well as the interactions between the two.
First, we would treat freshly isolated human NK in vitro with IL-2 doses
that would correspond to low-dose IL-2 therapy that induces expansion of
peripheral regulatory T cells in vivo. We would measure rate of proliferation, the
expression of activating receptors such as NKG2D, and their in vitro cytotoxicity
against osteosarcoma cell lines. These values would be compared to those from
unstimulated NK cells and from NK cells treated with our standard dose of IL-2.
Second, we would treated freshly isolated regulatory T cells with the same doses
and compare their rate of proliferation and their expression of defining T cell
markers. We would be particularly interested in determining if low-dose IL-2
stimulates regulatory T cell proliferation at higher levels than high-dose IL-2
treatment. Subsequently, we would determine the effect of low-dose stimulated
regulatory T cell as well high-dose stimulated regulatory T cells on NK
cytotoxicity by co-culturing them with NK cells that had been untreated or treated
with low-dose or high-dose IL-2.
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Osteosarcoma cell lines and culture
Human osteosarcoma cell lines KRIB, LM7, CCH-OS-D, U2OS, and TE85 and mouse K7M3 cells were cultured in complete Dulbecco’s Modified Eagle’s
Medium (Whittaker Bioproducts Inc., Walkersville, MD) supplemented with 2
mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 1 mmol/L nonessential amino
acids, 2 mmol/L minimal essential medium vitamin solution and 10% heatinactivated bovine serum (Intergen, Purchase, NJ). LM7 is a human
osteosarcoma lung metastatic cell line that was created in our laboratory by
repeated intravenous recycling of its parent cell line SAOS-2, through nude mice
lungs [64]. CCH-OS-D cells were kindly provided to us by Dennis Hughes, MD,
PhD (Division of Pediatrics, The University of Texas MD Anderson Cancer
Center). K7M3 mouse osteosarcoma cell line was created in our laboratory by
injecting K7M2 intravenously into BALB/C mice and harvesting the lung
metastasis [97]. All cell lines were mycoplasma-negative and validated by short
tandem repeat DNA Fingerprinting using the AmpFLSTR Identifier kit (Applied
Biosystems, Carlsbad, CA). The authenticity of cells was determined by the
Characterized Cell Line Core at The University of Texas MD Anderson Cancer
Center.
Human NK cells: Isolation, ex vivo expansion and culture
Blood samples were obtained from healthy adult volunteer donors (Gulf
Coast Regional Blood Center, Houston, TX) following informed consent. Human
NK cells were harvested from buffy coat fractions using the RosetteSep Human
NK Cell Enrichment Cocktail (Stem Cell Technologies, Vancouver, BC) and

102

Ficoll-Paque PLUS (GE Healthcare Life Sciences, Little Chalfont, UK) [39]. NK
cells were cultured in RPMI medium (Cellgro/Mediatech, Manassas, VA)
supplemented with 10% heat-inactivated bovine serum (Intergen), 2 mmol/L
glutamine, 1 mmol/L sodium pyruvate and 50 IU/ml recombinant human IL-2
(Proleukin, Novartis, Inc., Basel, Switzerland). Genetically-engineered K562 cells
with membrane-bound IL-15 and membrane-bound IL-21 were used as artificial
antigen presenting cells [aAPC] after 100-Gy g-irradiation for in vitro expansion of
isolated human NK Cells [39]. Every 3 days cultures were refreshed with media
changes. Every 7 days the cultures were re-stimulated with K562s at 1:2 PBMC
to aAPC ratio. When further NK cell purity or T cell depletion was required, third
party red blood cells were added to enhance agglutination and to remove
unwanted cells [129].

Flow Cytometry
The phenotypes of expanded NK cells were analyzed weekly using flow
cytometry. Phycoerythrin [PE]-conjugated mouse anti-human NKG2D, PEconjugated mouse anti-human CD16, PE-conjugated mouse anti-human CD3,
and Allophycocyanin [APC]-conjugated mouse anti-human CD56 (BD
Pharmingen, San Diego, CA) were used to monitor NK cell phenotype. For direct
surface staining, NK cells were suspended in FACS buffer (PBS, containing 2%
fetal calf serum and 0.1% sodium azide) and incubated with the indicated
antibodies for 20 minutes at 4°C. Data was acquired using a FACSCalibur
cytometer (BD Biosciences, San Jose, CA) and analyzed using the FlowJo
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software (Tree Star, Inc., Ashland, OR). APC and PE-conjugated isotype-control
IgG antibodies were used as negative controls (BD Pharmingen). Human NK
Cells were defined as CD56+, CD16+, NKG2D+ and CD3-. A purity of at least 95%
was deemed appropriate for further use.
Fluorescein isothiocyanate (FITC)-conjugated mouse anti-human HLAABC (BD Pharmingen), PE-conjugated mouse anti-human MIC A/B (BD
Pharmingen), PE-conjugated mouse anti-human ULBP2/5/6 (R&D Systems,
Minneapolis, MN), PE-conjugated mouse anti-human ULBP3 (R&D Systems),
and (PE)-conjugated mouse anti-human ULBP1 (R&D Systems) were used to
determine HLA and NKG2D ligand expression on human osteosarcoma cells. For
direct surface staining, osteosarcoma cells were suspended in FACS buffer
(PBS, containing 2% fetal calf serum and 0.1% sodium azide) and incubated with
the indicated antibodies for 20 minutes at 4°C. Data was acquired using a
FACSCalibur cytometer (BD Biosciences) and analyzed using the FlowJo
software (Tree Star, Inc.). APC, FITC and PE-conjugated isotype-control IgG
antibodies were used as negative controls (BD Pharmingen).
To determine the percentage of proliferating human NK cells, single-cell
suspensions derived from nu/nu mice lungs, liver, spleen and bone marrow were
stained with PE-conjugated mouse anti-human NKp46 (BD Pharmingen) and
FITC-conjugated mouse anit-BrdU (eBiosciences, San Diego, CA). For cell
surface staining, cells were suspended in FACS buffer (PBS, containing 2% fetal
calf serum and 0.1% sodium azide) and incubated with the anti-NKp46 antibody
for 20 minutes at 4°C. Cells were then permeabilized in 70% ethanol for 30
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minutes on ice, followed by Brdu intracellular staining in FACS buffer (PBS,
containing 2% fetal calf serum and 0.1% sodium azide) with anti-Brdu incubation
for 20 minutes at 4°C. Data was acquired and analyzed as described above.
Cytotoxicity Assays

NK mediated-cytotoxicity against osteosarcoma cells following a four hour
co-incubation period was measured using a [3H]thymidine incorporation assay
[130]. Radioactive incorporation was quantified using the Beckman Coulter® LS
6500 Multipurpose Scintillation Counter (Brea, California). The percentage of
cytotoxicity was calculated by the following formula: % of cytotoxicity = [(A B)/A]
× 100. A is the radioactivity in counts per minute [cpm] of osteosarcoma cells
treated with medium alone, and B is the radioactivity cpm osteosarcoma cells
treated with human NK cells.
To determine the importance of NKG2D-ligand interaction, cytotoxicity
assays were performed where NKG2D or a NKG2D ligand was blocked.
Osteosarcoma cells were plated in triplicate on 96-well plates labeled with 0.2
Ci/well of [3H] thymidine for 24 hours at 37°C, washed twice with PBS and then
incubated with 0 µg/mL, 5 µg/mL, or 10 µg/mL mouse anti-human ULBP2/5/6
(R&D Systems) for 24 hours at 37°C. The cells were then washed twice with PBS
and co-cultured with increasing concentrations of human NK cells for 4 hours at
37°C, incubated with 0µg/ml, 5µg/ml, or 10µg/ml mouse anti-human NKG2D
(R&D Systems). Prior to co-culture with osteosarcoma cells, NK cells were
incubated with mouse anti-human NKG2D (R&D Systems) for 1 hour at 37°C.
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[3H] thymidine radioactive incorporation and cytotoxicity were quantified as
described above.
Patient Osteosarcoma Samples

Microarray slides from paraffin-embedded osteosarcoma tumor specimens
contained 47 primary osteosarcoma samples and 56 osteosarcoma pulmonary
metastasis samples. The institutional review board approved medical record
reviews for the current study. (Originally published in Pediatric Blood and Cancer
2013. This material is reproduced with permission of John Wiley & Sons, Inc.)
To evaluate immunohistochemical evidence for NKG2D ligand expression,
these microarray tissue sections were deparaffinized in xylene and rehydrated.
Incubation at 95°C in citrate buffer for 20 minutes was conducted for antigen
retrieval. Incubation with 3% H2O2 for 12 minutes was performed to block against
endogenous peroxidase followed by protein block with 4% fish gelatin in PBS.
Sections were incubated with 50µg/ml recombinant human NKG2D/Fc Chimera
(R&D Systems) overnight at 4°C. Horseradish peroxidase goat anti-human
secondary antibody (Jackson ImmunoResearch, Inc., West Grove, PA) was then
applied for one hour at room temperature [RT] at 1:500 dilution in protein block,
followed by 3,3#-diaminobenzidine [DAB] 10 minute incubation and light
counterstain with hematoxylin. Sections not exposed to recombinant human
NKG2D/Fc Chimera served as negative controls. The expression of the NKG2D
ligand ULBP2 is high in terminally differentiated cells in normal human cervix
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epithelium [131]. Thus, sections of normal human cervix epithelium (US Biomax
Inc., Rockville, MD) were used as positive control.
Animal studies
All animal experiments were approved by the Institutional Animal Care
and Use Committee at MD Anderson Cancer Center. Female four-week old
athymic nu/nu mice and BALB/C mice were purchased from the Natural Cancer
Institute (Bethesda, MD). All mice were housed in standard cages, at five mice
per cage.
Aerosol treatment was performed as described previously [132]. PBS
suspension (10 ml) with or without recombinant human IL-2 [IL-2] (TECINTM
Teceleukin, Bulk Ro 23-6019, National Cancer Institute, Frederick, MD) was
added to an AeroTech II nebulizer (CIS-USA, Bedford, MA). The nebulizer was
operated at a flow rate of 10 liters of air per minute. Mice were placed
unrestrained in a sealed plastic cage and exposed to the aerosol for one hour.
The aerosol particles were generated with 5% CO2-enriched air obtained by
mixing normal air and CO2 with a blender (Bird3M, Palm Springs, CA). The CO2
concentrations were calibrated with a Fluid Fyrite (Bacharach, Inc., Pittsburgh,
PA).
To determine human donor NK cell retention in mouse lungs without
metastasis, 2 groups of nu/nu mice were treated with aerosol IL-2 @ 2000 U or
aerosolized PBS. We injected 50 million CM-DiITM (Molecular Probes, Eugene,
OR)-labeled human NK cells/mouse intravenously through the tail vein. Aerosol
treatment was administered 24 hours prior to NK cell injection, the day of NK cell
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injection, and then every other day for 1 week. Mice were killed 1 day, 3 days or
1 week after NK injection. The lungs, spleen, liver, heart and kidneys of the mice
were removed, embedded in Tissue-Tek optimum cutting temperature compound
[OCT] (Fischer Scientific, Hampton, NH), and frozen. Lungs were expanded with
OCT: PBS at a 1:1 dilution before freezing. (Originally published in Pediatric
Blood and Cancer 2013. This material is reproduced with permission of John
Wiley & Sons, Inc.)
In order to compare the proliferation of human donor NK cells in mice, 2
groups of nu/nu mice were injected with 50 million human NK cells and treated
with either aerosol IL-2 @ 2000 U or aerosolized PBS as described above. Mice
were killed 24 and 72 hours after NK cell intravenous injection. They were
injected intraperitoneally with BrdU (Invitrogen, Carlsbad, CA) 3 hours prior to
euthanasia. The lungs, spleens and livers were harvested and minced. Singlecell suspensions were prepared by passage through cell strainers (BD
Biosciences). Bone marrow cells were obtained by flushing femurs and iliac crest
with ice cold PBS. Red blood cells were lysed by incubating single cell
suspensions in Ammonium Chloride Solution (StemCell Technologies,
Vancouver, BC).
In order to assess acute and chronic toxicity of aerosol IL-2,
immunocompetent BALB/C mice were treated with either aerosol IL-2 @ 2000 U
or aerosol PBS every other day for 1 week. Mice were killed 3 days and 1 week
after the start of treatment and 1 month after the treatment ended. The lungs,
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spleen, liver, heart and kidney of the mice were removed, fixed in formalin, and
embedded in paraffin.
To determine the therapeutic effect of aerosol IL-2 + human NK cells on
lung metastasis, 3 million LM7 cells/mouse were injected intravenously through
the tail vein of nu/nu mice. The presence of micrometastasis was confirmed at 5
weeks in a group of 3 mice. Treatment was then initiated with aerosol PBS,
aerosol IL-2, aerosol PBS + human NK cells or aerosol IL-2 + human NK cells 6
weeks after LM7 injection. Aerosol therapy continued every other day for 5
weeks. NK cell injections (5 x 107 cells/mouse) were given 2 times a week
starting 1 day after the first aerosol treatment. Mice were sacrificed 5 weeks after
start of treatment. Lungs were extracted, expanded with OCT:PBS at a 1:1
dilution, embedded in OCT and frozen. Spleen, liver, heart and kidneys were
removed, fixed in formalin and embedded in paraffin. (Originally published in
Pediatric Blood and Cancer 2013. This material is reproduced with permission of
John Wiley & Sons, Inc.). Ten animals were used per group. This experiment
was repeated twice to verify results. Data shown is representative of one
experiment.
To assess aerosol IL-2 toxicity, complete blood count [CBC] and liver
enzyme blood chemistry were analyzed in nu/nu mice that were treated with
aerosol PBS or aerosol IL-2. Serum IL-2 concentrations were determined using a
Human IL-2 High Sensitivity ELISA kit (eBioscience), with absorbance measured
using a SpectraMax Plus384 Absorbance Microplate Reader (Molecular Devices,
Sunnyvale, CA). (Originally published in Pediatric Blood and Cancer 2013. This
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material is reproduced with permission of John Wiley & Sons, Inc.) Three mice
were used per treatment group.
Survival studies were performed using 10 nu/nu mice per group using the
same method as described above to establish lung metastasis. The presence of
micrometastasis was confirmed at 5 weeks in a group of 3 mice. Treatment was
then initiated as described above and continued for 5 weeks. Aerosol PBS,
aerosol IL-2, aerosol PBS + NK cell and aerosol IL-2 + NK cell treated mice were
observed to determine their survival rates.

Immunofluorescence
To determine the presence of CM-DiI-labeled human NK cells in mouse
organs following therapy, frozen sections of lung, spleen, liver, kidney and heart
were fixed in acetone and stained with Hoechst33342 nucleic acid stain
(Molecular Probes) at a 1:10,000 dilution in PBS. The corresponding organs of
mice not treated with CM-DiI-labeled human NK Cells were used as the controls.
(Originally published in Pediatric Blood and Cancer 2013) This material is
reproduced with permission of John Wiley & Sons, Inc.)
Frozen sections of lung with LM7 osteosarcoma metastasis were also
examined for the presence of NK cells using anti-human NKG2D antibody.
These frozen sections were incubated with 5% horse serum and 1% goat serum
in PBS for 30 minutes and then incubated overnight 4°C with AffiniPure Fab
Fragment goat anti-mouse IgG (Jackson ImmunoResearch, Inc.). Sections were
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then incubated overnight at 4°C with mouse anti-human NKG2D (eBioscience),
followed by incubation with goat anti-mouse Alexa Fluor® 546 (Molecular
Probes) at RT for 1 hour and then with Hoechst33342 blue (Molecular Probes)
for ten minutes. Negative controls were made by omission of the primary
antibody. Mean fluorescence per field was quantified in 5 random fields for each
section by using the Simple PCI software (Hamamatsu, Inc., Bridgewater, NJ).
Mouse NK cells present in LM7 osteosarcoma metastasis were visualized by
immunofluorescence using (PE)-conjugated rat anti-mouse NKp46 (BD
Pharminogen) as described above.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) staining.
Frozen tumor sections were fixed with 4% paraformaldehyde and
incubated with Proteinase K (Promega DeadEnd Fluorometric TUNEL System,
Fitchburg, WI) for 10 minutes, incubated with 3% H2O2 for 12 minutes to block
endogenous peroxidase, and then incubated over night at 4°C with recombinant
terminal transferase (Promega DeadEnd Flourometric TUNEL System) and
biotin-16-dUTP (Roche Applied Sciences, Indianapolis, IN). Sections were then
treated with 2% bovine serum albumin plus 5% normal horse serum in distilled
water for 10 minutes, followed by 30-minute incubation with 4+Streptavidin-HRPLabel (Biocare Medical, Concord, CA). This was followed by a DAB 10 minute
incubation and light counterstain with hematoxylin. Mean positive TUNEL
staining was quantified by the Simple PCI software (Hamamatsu, Inc.) in 5
random fields for each section.
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Statistical analysis
The unpaired Student’s t-test was used to evaluate the significance of
differences between experimental groups with a Gaussian distribution of values.
The Mann-Whitney U rank sum was used to evaluate the significance of
differences between experimental groups with non-Gaussian distribution of
values. The inverse correlation between apoptosis and tumor number was
evaluated using Spearman’s rank correlation test and a linear regression
analysis. P<0.05 was considered significant. Survival studies were analyzed
using the log-rank test.
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Presence of regulatory T cells in the NK cell population

One concern behind any use of IL-2 treatment is the inadvertent activation
of regulatory T cells [126], which can limit the immune anti-tumor response.
Regulatory T cells are known to suppress the immune response [133, 134], as
well as specifically inhibit NK cell activity [83, 135]. Regulatory T cells are defined
as CD4+CD25+Fxop3+ T cells [136]. Work performed by current lab member Ling
Yu, MD (Division of Pediatrics, The University of Texas MD Anderson Cancer
Center) demonstrated that aerosol IL-2 @ 2000 U treatment, given every other
day for 15 days to immunocompetent BALB/C mice would increase both CD4+
and CD8+ T cells in the lung parenchyma. The number of CD4+Foxp3+ T cells
was also increased, but their increase was proportional to the overall increase in
the number of CD4+T cells (unpublished data). Since aerosol IL-2 did not
increase the percentage of CD4+Foxp3+ T cells among CD4+ T cells, we do not
expect the presence of regulatory T cells to hinder the aerosol IL-2 treatment.
Since we used interleukin-2 to expand human NK cells, we wanted to rule
out any contamination with and subsequent expansion of regulatory T cells in our
ex-vivo expanded NK population. We stained for the presence of regulatory T
cells in our NK population at different time-points during expansion. Regulatory T
cells can be identified as CD4+CD25+CD127(low/-)[137]. We stained the NK
population with Phycoerythrin [PE]-conjugated mouse anti-human CD25 (BD
Biosciences), Allophycocyanin [APC]-conjugated mouse anti-human CD4 (BD
Pharmingen ) and Fluorescein isothiocyanate (FITC)-conjugated mouse anti-
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human Cd127(BD Pharminogen). Data was acquired using a FACSCalibur
cytometer (BD Biosciences) and analyzed using the FlowJo software (Tree Star,
Inc.). The percentage of regulatory T cells among our expanded NK population
was minimal (Figure A1). Freshly isolated PBMCs from buffy coats contain 0.1 %
± 0.018 regulatory T cells. Expansion for one week significantly increases this
percentage to 1.4% ± 0.15 (P = 0.01). This percentage declines to 0.98% ± 0.32
at 2 weeks of expansion and subsequently declines to 0.17% ± 0.12 after 3
weeks of expansion. There was a significant decline in the percentage of
regulatory T cells when we compare the population from week 1 and week 2 to
the population from week 3 (P = 0.007, P = 0.045; respectively). This
demonstrates that, although IL-2 treatment increases the ex vivo regulatory T cell
population initially, the effect is not sufficient to go in par with NK cell expansion.
We believe this low percentage of regulatory T cells will not significantly impair
NK cell function. All of our NK cell studies were performed with human NK cells
that had been expanded for 3 weeks.
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Figure A1: Regulatory T cell population during human NK cell ex vivo expansion. Ex
vivo human NK cell populations were monitored for the presence of regulatory T cells. P<0.5
was considered significant
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